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Low-and-middle-income countries (LMICs) have a higher mortality-to-incidence 
ratio for breast cancer compared to high-income countries (HICs) because of late-stage 
diagnosis. Mammography screening is recommended for early diagnosis, however, current 
screening guidelines are only generalized by economic disparities, and are based on 
extrapolation of data from randomized controlled trials in HICs, which have different 
disease burdens and all-cause mortality compared to LMICs. Moreover, the infrastructure 
capacity in LMICs is far below that needed for adopting current screening guidelines. This 
study analyzes the impact of disease burden, infrastructure availability, and other cause 
mortality on optimal mammography screening schedules for LMICs. Further, these key 
features are analyzed under the context of overdiagnosis, epidemiologic/clinical 
uncertainty in pathways of the initial stage of cancer, and variability in technological 
availability for diagnosis and treatment. It uses a Markov decision process (MDP) model 
to estimate optimal schedules under varying assumptions of resource availability, applying 
it to six LMICs. Results suggest that screening schedules should change with disease 
burden and life-expectancy. For countries with similar life-expectancy but different disease 
burden, the model suggests to screen age groups with higher incidence rates. For countries 
with similar incidence rate and different life expectancy, the model suggests to screen 
younger age groups for countries with lower life-expectancy. Overdiagnosis and 
differences in screening technology had minimal impact on optimal schedules. Optimality 
of screening schedules were sensitive to epidemiologic/clinical uncertainty. Results from 
this study suggest that, instead of generalized screening schedules, those tailored to disease 
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burden and infrastructure capacity could help optimize resources. Results from this study 
can help inform current screening guidelines and future health investment plans. 
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INTRODUCTION AND BACKGROUND 
 
1.1. Global burden of breast cancer 
Breast cancer is the most common and frequent cancer in women, and as per World 
Health Organization (WHO), it is impacting around 2.1 million women each year and 
resulting in the highest number of cancer-related deaths globally. (1) WHO estimated that 
627,000 women died from breast cancer in 2018, resulting in approximately 15% of deaths 
due to cancer among women. (1) This number is estimated to rise by 30% by the year 2030, 
resulting in approximately 817,361 deaths due to breast cancer. (2) The incidence of breast 
cancer is also estimated to rise by 26% by 2030 from 2018 breast cancer incidence data, 
which means a total of 2.6 million new cancer cases in the year 2030. (2) Approximately 
70% of deaths from cancers occur in low- and middle- income countries (LMICs) which 
can partly be associated with late-stage diagnosis when survival is minimal, about 70-90% 
of breast cancer cases in LMICs get diagnosed in late stages compared to 40% in the United 
States (US). (3-5) However, only 5 % of global health resources directed towards cancer 
are spent in LMICs. (6)  
However, there exist evidence-based strategies for the prevention of cancer-related 
deaths. Early diagnosis of cancers through screening, followed by treatment, reduced 
mortality rates in the US by 38 % for breast cancer. (7) Breast cancer could be detected at 
early stages through two strategies- early diagnosis and screening. Early diagnosis is based 
on improved public and professional awareness of signs and symptoms associated with 




systematic use of testing, such as mammography, ultrasound, to detect cancer across an 
asymptomatic population and treat cancer at early stages to prevent cancer-related deaths. 
(8) 
1.2. WHO recommendation of screening by age and resource setting (8)  
Current screening guidelines recommended by WHO are based on age groups and 
available health resources in the country. For suggesting mammography screening 
guidelines, WHO has considered three different age groups being women in age groups 
40-49, 50-69 and 70-75 and under three different resource settings being well-resourced, 
limited resource settings with relatively strong health systems and limited resource settings 
with weak health systems.  
 For the age group 50-69 in a well-resourced setting; WHO recommends organized 
and population-based mammography screening once every two years. Screening every two 
years seems to provide the best trade-off between benefits and harms. WHO also suggests 
considering organized, a population-based mammography screening program for women 
aged 50−69 years in limited-resource settings with relatively strong health systems if 
healthcare can implement the organized program of implementing biennial screening. 
However, in limited-resource settings with weak health systems, WHO suggests going for 
clinical breast examination as mammography screening strategies are not cost-effective in 
these settings.  
 For women in the age group 40-49, WHO suggests an organized population-based 
screening in an excellent or useful resource setting area in the context of rigorous research, 




mammography screening for this age group. Randomized control trials suggest that breast 
cancer mortality gets reduced if women between the age group 40-49 get screened; 
however, cancer incidence rates are less in this age group, which results in relatively 
smaller benefits. (8) Also, the sensitivity of mammography is low for this age group 
resulting in a greater number of false positives, i.e., a greater number of harms and more 
cost associated with it. (8) Further optimal screening interval for this age group is also 
uncertain. So, per WHO, to implement screening for this age group, more evidence-based 
research is required. In limited-resource settings with weak or relatively strong health 
systems, WHO recommends against the implementation of a population-based screening 
program for the age group 40−49 years. In limited-resource settings, implementation of 
health interventions promising great health benefits is advised. In these resource settings 
for the age group 40-49, clinical breast examination, which is a low-cost method, can be 
implemented.  
 For women in the age group 70-75, in a well-resourced setting, WHO suggests an 
organized population-based screening in adequate resources setting areas in the context of 
rigorous research. There is uncertainty regarding the trade-off between harms and benefits 
of mammography screening for women above age 70 as well because of the limited and 
low level of available evidence. Per existing data, the number of overdiagnosis and 
overtreatment associated with mammography screening is significantly high for this age 
group as compared to the age group of 50-69. (8) In limited-resource settings with weak or 
relatively strong health systems, WHO recommends against the implementation of 
population-based screening programs for women aged 70−75 years. Because the limited 




is a greater level of uncertainty about the effect of these programs in limited-resource 
settings. So, for this age group, WHO recommends implementing interventions with less 
cost associated.   
These mammography screening guidelines for breast cancer by WHO are informed 
through a systematic review of various randomized control trials (RCTs) and observational 
studies (OS). (8) All these RCTs and OSs are conducted in high-income countries (HICs). 
Also, to suggest optimal screening interval data results from both modeling study and 
RCTs are compared. The results from modeling study where six models were developed 
independently within the Cancer Intervention and Surveillance Modeling Network 
(CISNET) of the National Cancer Institute for the United States population (9) were 
compared with results from various RCTs conducted in different HICs. In the CISNET 
study, different predefined screening strategies with different starting and ending age of 
screening and different screening intervals were compared. Similarly, RCTs were also 
conducted for different age groups and with different screening intervals in different HICs. 
(10-15)The implementation of these guidelines has led to considerable decreases in cancer-
related mortality in HICs. 
1.3. Challenges of breast cancer screening in LMICs 
Unlike in HICs, cancer control in LMICs is generally neglected and the evidence 
base to guide strategies for breast cancer control in LMICs is limited and of poor quality. 
(16) Current guidelines developed for LMICs are extrapolations of models on HICs as the 
quality of data collected from evidence-based studies conducted in LMIC is generally 




implemented in LMICs because disease burden, health care system and budget are different 
across countries. (16)  
To address above mentioned gap, a study developed new parametrization methods 
for limited data settings with little to no screening, such as LMICs. (17) It provided the 
framework for developing a model for the analysis of screening guidelines. For which 
Markov decision process model was developed for the analysis of screening guidelines to 
base the analysis on resource availability and disease burden. (18) However, in this study 
several gaps are not considered such as overdiagnosis, epidemiologic/clinical uncertainty 
in pathways of the initial stage of cancer, variability in technological availability for 
diagnosis and treatment, and workforce training in LMICs. This thesis will be addressing 
these gaps while evaluating screening guidelines for LMICs.  
Chapter 2 presents a literature review on cost-effective studies for informing 
population-level breast cancer screening strategies in HICs, studies informing personalized 
screening strategies for women in HICs and cost-effective studies for informing 
population-level breast cancer screening strategies for LMICs. Chapter 3 discusses the 
research gaps and research goals in detail. Chapter 4 presents methodology used to address 
research gaps. Chapter 5 presents the results followed by discussion and conclusion in 







As discussed in the Introduction and Background, the disease burden is high in 
LMICs, and limited studies get conducted in these areas. In this chapter, several studies 
conducted in the realm of cancer screening will be discussed.  
2.1. Cost-effectiveness studies of population-level breast cancer screening strategies 
in high-income countries 
The section below provides a brief description of a number of studies that have 
done a cost-effectiveness analysis of breast cancer screening scenarios for HICs. Most of 
these studies involve developing mathematical models specific to HICs to inform 
population-level screening guidelines. Some of the studies used Markov processes to 
estimate the natural history of cancer by fitting clinical data and through simulation of the 
Markov processes studied different screening scenarios comparing their benefits, harms, 
and costs.  Other studies used published data for simulating natural history of breast cancer 
and then developed mathematical models to compare different screening scenarios.  
Ahern and Shen (19) used a microsimulation model to generate a life history of 
500,000 women, and every woman’s life history was simulated independently. For every 
woman who develops breast cancer in their lifetime, they used published data for 
simulating a natural history of breast cancer. In this study, they compared ten different 
mammography screening strategies and ten different clinical breast examination strategies 
suggested by the American Cancer Society, National Cancer Institute, and the US 




quality-adjusted life years (QALYs) and expected total medical costs per woman and 
compared these strategies using incremental cost-effectiveness ratios. This study 
concluded that screening strategies with lower costs should be considered for future 
screening guidelines 
A study by Ayvaci and Alagoz, (20) focuses on cost-effectiveness analysis of 
diagnostic decisions in the context of breast cancer after mammography for which a finite-
horizon discrete-time constrained Markov decision process (MDP) model was developed 
in order to maximize the total expected QALYs of a patient under resource constraints. 
Clinical data were used to estimate the parameters of the MDP model, and it was solved as 
a mixed-integer program. After repeating optimization for a sequence of budget levels, 
incremental cost-effectiveness ratios were calculated, and comparison was made with 
actual clinical practice with optimal decisions. This study allows policymakers to find 
optimal diagnosis action under given budget restrictions and optimally allocate the 
resources.  
The study by Koleva-Kolarova et al., (21) evaluates the benefits, harms, and cost-
effectiveness analysis of decreasing starting age of mammography screening for Dutch 
women, i.e., changing the starting age of screen to either 46 or 48 instead of 50 and 
performing biennial screening till age 74. For which they developed a simulation model to 
calculate life years saved, false-positive rates, deaths prevented, and costs for these 
screening scenarios and did the cost-effectiveness analysis. The results of the study suggest 





Gocgun et al. (22), in a similar study, developed a multi-state Markov model for 
the natural history of breast cancer and used a simulation model to study the cost-
effectiveness analysis of breast cancer screening policies for the Canadian population. 
Their model suggests that screening women in the age group 50-59 and 60-69 once in five 
years is more cost-effective as compared to screening women in the age group 40-49 and 
cost per life-years saved increases with an increase of frequency of screening. 
Maillart et al., (23) formulated a partially observed Markov chain model to study 
the age-based dynamics such as incidence rate in premenopausal women versus 
postmenopausal women and accuracy of test results for the US population. In this study, 
they evaluated various screening scenarios of varying screening frequencies and age 
intervals to find efficient scenarios by generating an efficiency frontier measured by 
lifetime mortality risk and expected mammogram count.  
Mandelblatt et al. (9) with an objective to evaluate US breast cancer screening 
strategies, analyzed 20 predefined screening scenarios with varying starting and ending age 
applied annually and biennially by comparing the outcomes from six different models 
developed independently within the Cancer Intervention and Surveillance Modeling 
Network (CISNET) of the National Cancer Institute. For all the predefined policy outcomes 
such as the number of mammograms, reduction in deaths from breast cancer or life-years 
gained (vs. no screening), false-positive results, unnecessary biopsies, and overdiagnosis 
were evaluated using all six models and to find the efficient policies, efficiency frontiers 
were plotted. Their analysis shows that biennial policies had more benefits and fewer harms 




Rafia et al. (24) develop a mathematical model for the natural history progression 
of breast cancer up to diagnosis and a postdiagnosis model for treatment, recurrence, and 
survival from the disease. In the study, the model was used to evaluate the impact of 
increasing the terminating age of screening for the UK population. For which they did the 
cost-effectiveness analysis of different screening scenarios by increasing the recommended 
ending age of screening from 70 to72, 75, 78, 81, 84, 87, and 90 years. Monte-Carlo 
sampling approach was used to calculate the costs and benefits of the above-mentioned 
scenarios. The cost-effectiveness analysis suggests that ending age for breast cancer 
screening can be further increased to 78 years for the UK based on the willingness-to-pay 
thresholds.  
Rojnik et al. (25) developed a time-dependent Markov model for breast cancer to 
determine the most cost-effective screening policy for population-based mammography 
breast cancer screening for the Slovenian population. In this model, 12 different screening 
strategies with different starting and ending age and with a screening interval of 1 year, 
two years, and three years, i.e., a total of 36 policies were evaluated. For all the screening 
scenarios, costs and benefits were evaluated, and after cost-effectiveness analysis, the 
optimal policy for the Slovenian population in screening women between the age group 40 
to 80 years with three years screening interval for willingness-to-pay per QALY is $50,000. 
Rue et al. (26) used a previously developed mathematical model (27) to estimate 
the cumulative probability of death for a cohort exposed to different screening strategies 
after specified years of follow-up and for no screening scenario. These probabilities were 
used to estimate breast cancer mortality reduction and years of life gained. They evaluated 




(Spain) population. As per their analysis, biennial screening strategies has 80% more 
mortality reduction as compared to annual screening scenarios and years of life gained on 
more for screening strategies starting at younger age groups as compared once ending at 
older age groups. 
Tosteson et al. (28) did the cost-effectiveness analysis for digital mammography 
screening for the US female population. For this analysis previously developed discrete-
event simulation model (29) was used to evaluate women age 40 and older with different 
interventions being all-film mammography screening, all-digital screening and targeted 
digital screening with age-targeted, digital for women less than 50 years, and age-density-
targeted, digital for women less than 50 years for not dense or digital for women with dense 
breasts. The cost-effectiveness analysis results show that all age digital mammography is 
less cost-effective than film mammography, whereas age-targeted digital mammography 
is more cost-effective, and density targeted digital mammography is more costly for 
women of older age groups.  
Wang et al. (30) in the study developed a mathematical model for US women to 
first estimating the individual risk of breast cancer-specific to women’s age and then based 
on the risk factor suggesting personalized mammography screening to the women. The risk 
estimation model is a regression model used to predict a woman’s probability of developing 
breast cancer at her current age based on several breast cancer risk factors. Risk factors 
included in the study are mainly age, race, Hispanic ethnicity, number of first-degree 
relatives with breast cancer, age at first childbirth, surgical menopause, use of hormone 
replacement therapy, menopausal status, BMI, previous breast procedure, and last 




population-based screening strategies by saving a greater number of life years. The model 
suggests that a combination of the risk factor of cancer is not the same across age groups 
which suggest different screening strategy for women of same age group. 
Stout et al. (31) used a discrete-time simulation model developed at the University 
of Wisconsin to evaluate lifetime cost and number of QALY for women aged 40 years or 
older, in the period of 1990 to 2000, for different breast cancer screening scenarios. They 
evaluated 64 different screening scenarios and no screening scenario and did a cost-
effectiveness analysis to find the most cost-effective screening strategies for the US.  
Lee and Zelen (27) developed a general probability model to predict the cumulative 
mortality which can be used to compare mortality rate for different screening schedule, 
explore the potential benefit of subpopulations, and compare relative reductions in disease-
specific mortality due to advances and dissemination of both treatment and early detection 
screening programs. They have applied this model to breast cancer in the study.  
2.2. Studies analyzing personalized screening of breast cancer for women in high-
income countries 
This section discusses the studies that were done for analyzing personalized 
screening scenarios for developed countries based on individual risk factors using 
mathematical models. Some of these studies did cost-effectiveness analysis for comparing 
personalized screening with population-level screening and suggesting the optimal 
decisions. While other studies suggested optimal follow-up step after initial screening 




these studies were for the countries where population-level screening guidelines are already 
in effect.  
Alagoz and Chhatwal, (32) developed a finite-horizon discrete-time Markov 
decision process model to optimize the post mammography diagnostic decisions such as 
biopsy or follow-up for an individual woman based on her probability of cancer, that 
maximizes her total expected QALYs. They compared the model generated results with 
the actual decisions made by radiologists, and their model suggested fewer regular follow-
ups than actual practice.  
Another similar study by Chhatwal and Alagoz (33) is based on developing a finite-
horizon discrete-time Markov decision process model to suggest when a woman should 
undergo biopsy based on her mammographic features and demographic factors such as the 
age of the women. The results from the model indicate that while making a decision related 
to biopsy, age plays an essential role as an older patient’s risk threshold for a biopsy is 
higher than that of a younger patient. 
Ayer and Alagoz, (34) proposed a personalized mammography screening policy for 
women based on prior screening history and personal cancer risk factors, for which they 
formulated a finite-horizon partially observable Markov decision process model. The 
results generated from the model were better than the current population-based guidelines 
as the personalized screening policy resulted in more total expected quality-adjusted life-
years saved and significantly fewer mammograms and false-positives. 
Gray et al., (35) in the study conceptualized the decision-analytic model (discrete 




program (NBSP) for personalized screening against standard screening in United Kingdom 
(UK), i.e., how cost-effective it would be to introduce personalized screening based on 
individual’s characteristics such as breast cancer risk factors or the performance of the 
screening modality for that individual. In this study cost-effectiveness analysis is done for 
four different stratified NBSPs- risk one , risk two , masking (supplemental screening for 
women with higher breast density), the existing UK NBSP- mammography screening 
women between age group 50 and 70 with a screening interval of three  years, and no 
screening. Their results suggest that risk one and risk two interventions are more cost-
effective as compared to current screening guidelines in the UK. 
O’Mahony et al. (36) in the study present a simple mathematical model to estimate 
the relationship between breast cancer incidence and the optimal cost-effective screening 
interval while accounting for imperfect screening sensitivity and specificity and a random 
duration of the preclinical disease state for suggesting personalized screening. They also 
verified and validated the results from their model with that of the MISCAN model. Their 
results show that disease risk can influence the optimal screening interval, such as the risk 
of breast cancer increases with age, and as per their model, screening interval will be 
shorter for older age groups. 
Madadi et al. (37) developed a randomized discrete-time finite-horizon partially 
observable Markov chain model to evaluate a wide range of screening mammography 
policies, incorporating heterogeneity in women’s adherence behaviors. Considering 
potential harms of mammography tests (e.g., risk of developing radiation-induced breast 
cancer, false negatives, false positives, etc.), policies with varying starting age, ending age, 




QALYs and the lifetime breast cancer mortality risk. This included three difference 
adherence levels for screening policies and evaluated the benefits and harms for the same. 
The results show that women with higher and perfect adherence have a lower risk of dying 
from breast cancer than women who have low adherence. Also, based on the patient 
characteristics and estimated adherence level, physicians can decide the interval of 
screening.  
2.3. Cost-effectiveness studies of population-level breast cancer screening strategies 
in low-and middle-income countries 
This section gives a brief description of the studies that are conducted for LMICs. 
Most of the studies are cost-effectiveness analysis of pre-selected screening strategies using 
the mathematical models or simulation models. These studies consider cost-effectiveness 
analysis of interventions like clinical breast examination or mammography screening at 
different screening intervals. Only the study by Kong et al. (38) developed a dynamic 
programming model to suggest a mammography screening strategy with a fixed number of 
lifetime screens for the Chilean population. All these studies analyzed population-level 
screening guidelines for LMICs. 
Zelle et al. (39) did a cost-effectiveness analysis for Ghana, where there is low 
awareness about breast cancer and has poor late-stage treatment resulting in more cancer 
deaths. To guide policymakers to select intervention policy specifically for Ghana, they 
used a mathematical model developed by Groot et al. (40) to estimate the costs and health 
effects of breast cancer interventions from the healthcare perspective. They evaluated 
eleven interventions relevant to breast cancer control in the Ghanaian context, all related 




study, clinical breast examination in combination with treatment for all cancer stages and 
mass media awareness-raising are the most cost-effective interventions for Ghana settings, 
whereas mammography screening of women aged 40–69 years is considered not cost-
effective.   
Another study related to cost-effectiveness analysis is presented in the cost-
effectiveness analysis of breast cancer control intervention in Peru by Zelle et at. (41). 
Where a mathematical model was developed to do the cost-effectiveness analysis for 
different pre-defined screening scenarios like triennial screening between age 45-69 and 
annual screening between age 40-69. Based on this analysis, the best intervention strategy 
was suggested, which is the most cost-effective. The study suggests a combination of 
intervention and different intervention strategies for urban and non-urban areas. 
Kong et al. (38) developed a dynamic programming model to suggest a 
mammography screening strategy with a fixed number of lifetime screens for the Chilean 
population in order to minimize the lifetime death rate from breast cancer. The results from 
the model suggest that for the Chilean population, two years interval screening strategies 
are less cost-effective as compared to three- and four-years screening intervals. The optimal 
ages to screen for fixed ten mammograms suggested by the model are 43, 47, 51, 54, 57, 
61, 65, 68, 72, and 76 years, and the most effective fixed inter-screening is every four years 
after age 40 years.  
Ullao et al. (42) developed a simulation model to study the cost-effectiveness 
analysis of mammography screening policies recommended by WHO in Mexico. In this 
model, women between age 25- 75 years were divided into the age groups of 5 years 




the resource constraints. All different three different screening frequencies- annual, 
biennial, and triennial were also considered for the study. The results from the analysis 
suggest screening women every three years with the starting age of screening being 40 
years and ending age being 70 years. However, for optimal utilization of resources, the 
screening coverage for all age groups varies from 15 – 25 % suggesting improving 
countries' health policies.  
A study by Ginsberg et al.,(43) included cost-effectiveness analysis of prevention 
and treatment strategies for breast cancer using mathematical modeling, based on a lifetime 
population model for sub-Saharan Africa and Southeast Asia. In this study, six 
interventions were compared with no screening scenario and were simulated for 100-years 
to calculate life years adjusted for disability (DALYs) and the total costs of breast cancer 
treatment and follow-up. The results from this study suggested that the intervention, 
treatment of all cancer stages in combination with mammography screening is cost-
effective. 
Groot et al. (40), in their study, did the cost-effectiveness analysis of six different 
breast cancer treatment interventions in three epidemiologically different world regions- 
Africa, North America, and Asia for which they developed a mathematical simulation 
model. For comparison, they evaluated DALYs and calculated average cost-effectiveness 
ratios for these interventions with that of no screening scenario and then calculated 
incremental cost-effectiveness ratios (CERs). Their results show that the intervention of 





Okonkwo et al. (44), in their study, conducted a cost-effective analysis of breast 
cancer screening policies for developing countries. In this study, a microsimulation 
screening analysis (MISCAN) model is used after calibrating the previously developed 
MISCAN model for the Dutch population-based on breast cancer incidence, stage 
distribution, and mortality data in India. The cost-effectiveness analysis was done for 
different predefined screening policies like a single test at age 40 or 50 or screening from 
age 40 to 60 or from age 50 to 70 (inclusive) with intervals of 5 years, two years, or one 
year using either clinical breast examination or mammography. The effects of screening 
are  expressed as the number of breast cancer deaths averted, the number of life-years 
gained, and the percent reduction of annual mortality achieved in the steady-state, which 
was reached approximately 15 years after the initiation of the screening program. A cost-
effectiveness analysis is done after comparing the cost-benefit of each screening scenario 
with no screening scenario, and after that, incremental cost-effectiveness ratios are 
calculated to find the most cost-effective policy.  Their results suggest that in India, 
screening from age 40 to 60 was more cost-effective than screening from age 50 to 70.  
Nguyen et al. (45) used the Markov model to compare the costs and effects of an 
annual screening program using clinical breast examination (CBE) with no screening on a 
cohort of 4,103,285 asymptomatic women aged 40 years based on 2008 population in 
Vietnam. The program analyzed the costs and life-years saved for these women assuming 
annual examination for 15 years. They did the incremental cost-effectiveness analysis by 
reducing the starting age to 35 and extending the ending age to 65. Their study shows that 




Sum et al. (46) developed a natural history Markov model for breast cancer to 
estimate the lifetime costs and effects of breast cancer screening for rural women in China 
from a societal perspective. Screening guidelines in China for rural women suggest clinical 
breast examination coupled with ultrasound as the primary tool of screening for women in 
the age group 35-64 years with screening frequency of 3 years. This study conducted the 
cost-effectiveness analysis of a base case, i.e., current guidelines, current guidelines with 
varying screening intervals such as screening every year, screening every five years, and 
no screening scenario after evaluating total costs and QALYs for all mentioned scenarios. 
The results of the analysis shows that for asymptomatic women in rural area of China 
screening is not cost-effective with current screening tools due to low breast cancer 
incidence in these areas however priority care should be given to symptomatic women so 
that they can get proper access to diagnosis and treatment at early stage of cancer, which 
will reduce the mortality due to cancer and harms associated with screening.   
Most of the screening strategies to detect cancer at early stages that are 
recommended for LMICs are developed based on data available from RCTs in HICs. RCTs 
provided the data for parametrizing the natural disease progression of breast cancer, and 
this data is unavailable in LMICs or the quality of data is generally poor.  
A recent study developed new parametrization methods for limited data settings 
with little to no screening, such as LMICs. (17) It provided the framework for developing 
a model for the analysis of screening guidelines. A Markov decision process model was 
developed to base the analysis on resource availability and disease burden. (18) This model 
can identify optimal mammography screening scenarios, i.e., what age should we screen a 




model is one that gives the best trade-offs between costs and benefits. Costs include 
screening costs, follow-up diagnosis costs for true-positives and false positives, and 
treatment costs. Benefits include quality-adjusted life-years (QALYs) saved compared to 
no screening. This model was applied to Peru.  
There are several gaps that remain unconsidered in this study such as lack of 
consideration of overdiagnosis, epidemiologic/clinical uncertainty in pathways of the 
initial stage of cancer, variability in technological availability for diagnosis and treatment, 
and workforce training in LMICs. All these gaps lead to the research goals that are 








This thesis aims to study the impact of difference in disease burden, other cause 
mortality and infrastructure availability on development of national level cancer screening 
guidelines.  Further, studying this under the issues of overdiagnosis, epidemiologic/clinical 
uncertainty in pathways of the initial stage of cancer, variability in technological 
availability for diagnosis and treatment, and workforce training in LMICs.  
Research on the former two concepts is only recently emerging for HICs driven by 
the increased disbenefits of already implemented screening, and therefore, accounting for 
these before implementation of screening programs in LMICs would be crucial to avoid 
the negative consequences observed in HICs. Considering the already strained 
infrastructure in LMICs these features can play a much significant role for LMICs.  
This thesis studies four research goals specific to the context of LMICs. 
• Analyzing optimal screening schedules by considering country-specific disease 
burden and resource availability - Comparative analysis of 6 countries with 
varying disease burden, all-cause mortality, and infrastructure availability 
In this study we conduct the comparative analysis for multiple LMICs that differ in 
disease burden, specifically incidence and all-cause mortality as previous studies have 
highlighted the impact of life expectancy on the benefits of screening. (9) We implement 
this study for central Latin America (Colombia), Andean Latin America (Peru), Eastern 
Sub-Saharan Africa (Uganda), Southeast Asia (India), South Asia (Philippines), and 




cancer observatory. We study the relationship between disease demographics and 
screening guidelines i.e. do screening guidelines changes with change in disease burden. 
These regions were selected based on the difference in disease burden (Figure 1), life-
expectancy and current infrastructure (Table 1). As we can see in the figure 1, Philippines 
has the higher incidence rates among other selected LMICs, Peru and Colombia have 
similar incidence rate and similar life-expectancy, India and Uganda also has somewhat 
similar incidence rate but Uganda has much lower life-expectancy and Kyrgyzstan has 
lowest incidence rate among these countries. 
 
Figure 1: Incidence per 1000 women in different disease burden regions 
Table 1 : Comparing life-expectancy, mammography resources, and current screening 
guidelines in different countries 
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• Analyzing the influence of overdiagnosis on changes in optimal screening 
schedules.  
Overdiagnosis is define as the detection of tumors that would not have been 
detected in a woman’s lifetime in the absence of screening. None of the models developed 
for LMICs that we are aware of included the consequences of overdiagnosis (cancer that 
may not progress to invasive cancer stages in lifetime), and in HICs research in this area is 
only recently emerging. Several recent studies for HICs have  highlighted the significance 
of overdiagnosis of screening, mainly in the early stages of cancer. (47-53) In the literature, 
mainly interpretation of results related to overdiagnosis of cancer at an early stage (in-situ) 
has raised concerns that overdiagnosis results in more harm than benefits by promoting 
anxiety and detecting cancer that may never progress and cause illness or death. (53) Also, 
overdiagnosis not only impacts the individual but also results in unnecessary follow-ups 




utilization, and budget allocations resulting in overburdening of the system, which is 
mostly a problem in LMICs where even current capacities are insufficient. Resources and 
expertise available in LMICs are limited to evaluate overdiagnosis and false positives, 
which requires careful monitoring and advanced technology. (8)  Further, no analysis has 
been done for LMICs to consider overdiagnosis while evaluating screening guidelines.  
• Studying the impact of the CIS pathway and sensitivity of mammography for 
diagnosis at CIS on optimal screening schedules and on benefits, harms, and costs. 
Under the context of over-diagnosis of cancers, some studies have highlighted the 
uncertainty around pathways of carcinoma-in-situ (CIS) stage and mammography 
sensitivity for diagnosis at this stage and their corresponding impact on the progression 
rate estimates for CIS. (51) CIS is initial cancer stage and can progress to invasive cancer 
if left untreated. Some of the studies have assumed that all invasive breast cancers progress 
through a pre-clinical in-situ state that can be detected at screening, whereas some studies 
have considered that some CIS first become visible on mammography as an invasive 
tumor, i.e., some cancer cases directly progress to detectable invasive cancer. Also, the 
studies have assumed that the sensitivity of mammography for diagnosis at the CIS stage 
is different than the sensitivity of mammography at other invasive stages. All the studies 
that have considered these uncertainties were done under the context of overdiagnosis as 
more cancer cases are getting diagnosed at in-situ stages after implementing screening 
interventions. Previous work (18) has only considered progressive CIS, and it has assumed 
that the sensitivity of mammography at diagnosis is same for all cancer stages, whereas 
sensitivity at CIS can vary from 30-90% of specified values. Different sensitivity of 




• Studying the impact of delay in availability of latest technology and expertise on 
screening schedules.  
 Sensitivity represents the ability of screening tests to detect people with the disease 
(true positive rate), and specificity is the ability of the test to detect those without the 
disease (true negative rate). Modality-specific sensitivity and specificity are the estimate 
of the accuracy of test results and depend on the technology and expertise of radiologists. 
Estimates from the breast cancer surveillance consortium (BCSC) suggest that 
mammography sensitivity and specificity have been increasing over time, representing the 
advancements in diagnostic tools. As a result, these values might not be the same under all 
resource settings and may vary with the availability of experienced radiologists or other 
diagnostic measures. Technology and expertise available in LMICs may not be the latest 
and can also contribute to the outcomes of national-level screening guidelines. Previous 
work (18) has assumed same sensitivity and specificity for both HICs and LMICs. So, there 
is a need to study the impact of the advancement of technology and expertise of radiologists 








The model presented in (17, 18) was used as the mathematical framework for the analysis 
of the 4 research goals in this thesis. We will first provide an overview of the natural disease 
progression of breast cancer in Section 4.1, overview of the model (17, 18) in Sections 4.2, 
and will discuss the methodological approach for analysis of the 4 research goals of this 
thesis in Section 4.3 followed by validation in section 4.4.  
4.1. Overview of breast cancer disease progression  
 
The model assumed that breast cancer initiates as carcinoma-in-situ (CIS), i.e., 
women can transition from healthy to CIS.  In the absence of a diagnosis, the disease 
naturally progresses through preclinical invasive carcinoma stages local, regional, and 
distant, that it is referred to as system states. From any of these preclinical disease states, 
women can transit to clinical states through diagnosis based on symptoms or through 
screening. Upon transition to a clinical state through diagnosis, women remain in the stage 
at diagnosis and faced a certain rate of death based on treatment efficacy at that cancer 
stage. For women who were diagnosed, the model did not explicitly consider the recurrence 
of disease but is only considered an average stage-specific rate of survival. The flow 
diagram of the model is presented in Figure 2. It assumed that onset rates, i.e., the rate of 
transition from healthy to CIS, and diagnostic rates, i.e., the rates of transition from 
preclinical to clinical states, are specific to a population, and for which a two-step Markov 




natural progression between cancer stages, i.e., between preclinical CIS to local, to 
regional, and to distant, do not vary by population and used pre-estimated rates from the 
literature. A brief overview of the process of estimating onset rates and diagnostic rates is 
presented in the next section, and more details are presented in Appendix A. 
 





4.2. Modeling framework used for the analysis of research goals 
The model has three main components, first is parameterization of natural disease 
progression using a two-step Markov process methodology developed specific to the data-
settings in LMICs, second is Markov decision process model to identify optimal screening 
schedules under varying resource constraints and finally after evaluating the optimal 
screening strategies, a simulation model (compartmental) which simulate Markov process 
model over 100 years was used to calculate multiple metrics to evaluate harms, benefits, 
and costs for screening scenarios. The parametrization model takes data input as age-
specific incidence and stage distribution of diagnosis for breast cancer and demographic 
projection from software, ‘Spectrum’ specific to the country. For the optimization model, 
input includes disease-related rates estimated from the parametrization model, costs, and 
mammography specific parameters. 
4.2.1. Overview of two-step Markov process (TSMP) methodology for 
parametrization of the natural onset and progression of cancer  
Parameterization of a cancer natural history model consists of estimation of three sets of 
parameters that vary by age: a) onset rates- the rates of transitioning from healthy to CIS; 
b) progression rates- the rates of transitioning between preclinical disease stages in the 
absence of diagnosis, and c) diagnostic rates- the current rates of diagnosis in the absence 
of intervention. The TSMP model, specifically developed for limited-data settings such as 
LMICs where longitudinal cancer registry databases are not available, is an integration of 
two Markov processes. Data that are usually available for most LMICs are only the 




of newly diagnosed cases of cancers and deaths per 1000 women, estimated through the 
Global Cancer Observatory. (54) There are usually no data on how people are diagnosed, 
which could vary according to population-specific parameters, such as population’s 
awareness and knowledge in recognizing symptoms and access to health care, in addition 
to disease-specific parameters such as occurrence of symptoms. Therefore, in this study, 
we used a new two-step Markov process methodology developed specifically for 
parameterization of cancer progression models in LMICs where longitudinal cancer 
registry databases are not available. (17) This method, under the assumption that 
progression rates are disease-specific and do not vary by population, uses pre-estimated 
progression rates from the literature (Appendix A), and estimates population-specific onset 
rates and diagnostic rates by fitting Markov process models to data on invasive cancer 
incidence and stage at diagnosis. The mathematical structure of the model generates onset 
rates to be representative of CIS cases that may or may not progress to invasive carcinoma 
within the lifetime of the individual, although it does not incorporate cases of CIS that may 
regress. The model generates diagnostic rates to be representative of the overall rates of 
diagnosis in the population, inclusive of the inverse of stage-dependent time for 
development of symptoms and time-delays in seeking care, and thus inclusive of 
population’s awareness to symptoms and access to care. Based on estimates in the literature 
(55), we assumed that progression rates are a logistic function of age, with progression 
being more aggressive at younger ages. Technical details of the theory and proofs of the 





4.2.2. Overview of Markov decision process (MDP) to identify optimal screening 
schedules for mammography 
MDP is a sequential decision-making model. Specifically, for any given screening 
schedule, it can evaluate the weighted average lifetime costs and benefits, weighted 
according to the probabilities of cancer onset by age and its progression under the influence 
of the screening schedule. Instead of identifying optimal screening schedules from among 
all possible combinations of age groups and screening intervals, the problem was 
formulated as a Markov decision process (MDP), and it was solved using dynamic 
programming (DP). 
The optimal screening schedule is defined as one that gives the best trade-offs 
between costs and benefits. Costs include screening costs, follow-up diagnosis costs for 
true-positives and false positives, and treatment costs. Benefits include quality-adjusted 
life-years (QALYs) saved compared to no screening. To convert benefits into the same 
metrics like costs, they are multiplied with a monetary value-per-QALY lived. Value-per-
QALY is a measure for the economic value added from health investments. (56) For any 
specific assumption for the value-per-QALY, an MDP model can identify the screening 
schedule, including the optimal number of lifetime screens, that give the best trade-offs in 
costs and benefits. It is be expected that as the value-per-QALY lived increases, the optimal 
schedule will have a higher number of lifetime screens. Researchers have suggested 
multiple assumptions for the value-per-QALY lived, several related to the GDP per capita 
of the country, and thus, could change over time and vary by country. (56) Therefore, 




QALY lived to generate a different optimal number of lifetime screens. Formulation of 
MDP model is presented in appendix B. 
4.3. Analysis of research goals 
4.3.1. Adding Overdiagnosis in the MDP model  
 Carcinoma in-situ (CIS) is a risk factor for invasive breast cancer. Earlier to the 
introduction of mammography screening, the disease was detected at invasive cancer 
stages rather than the CIS cancer stage. But the incidence of detecting cancer at CIS has 
increased, after the advent of screening mammography. However, the natural history of 
CIS is poorly understood as its onset, regression, and progression rates are not directly 
observable. (51) Some recent studies have assumed that some proportion of CIS cancer 
may progress to invasive, and others may remain non-progressive for a sufficiently long 
time for the patient to die of other causes. However, both progressive and non-progressive 
CIS are clinically detectable using mammography screening. 
To include non-progressive CIS in the previously developed MDP model, we 
assumed that a healthy person could either transit to preclinical progressive CIS or to 
preclinical non-progressive CIS. After screening, it can further transit to clinical 
progressive CIS or clinical non-progressive CIS, where a person will remain in either state 
until mortality. However, preclinical progressive CIS, if clinically not detected, may 
progress to preclinical invasive local cancer stage. Whereas preclinical non-progressive 
stage will remain in the same stage in the absence of screening.  We would be employing 




progressive CIS. We will be using the onset rates available from literature for preclinical 
non-progressive CIS. (57) 
Now, we will include preclinical non-progressive CIS and clinical non-progressive 
CIS states in the state space of the MDP model. We also assumed that follow-ups and 
treatment would be provided to the woman in the clinical non-progressive CIS cancer stage 
similar to that of the clinical progressive CIS cancer stage as we cannot differentiate 
between progressive and non-progressive cancer after detection so the same treatment and 
follow-up cost will be applicable for non-progressive CIS stage.  
After implementing the above changes, we will be using the MDP model described 
in section 4.2.2. to evaluate the optimal screening strategy for a given number of lifetime 
screens.  
4.3.2.  Impact of Uncertainty in disease pathways and mammography sensitivity of 
CIS 
  As discussed earlier, recent studies have used varying assumptions about CIS 
natural history pathways and their corresponding impact on CIS progression rates. (51) 
Some of the studies have assumed that all invasive breast cancers progress through a pre-
clinical in-situ state that can be detected at screening, whereas some studies have assumed 
that some CIS first become visible on mammography as an invasive tumor, i.e., some 
cancer cases directly progresses to detectable invasive cancer. Also, the studies have 
assumed that the sensitivity of mammography for diagnosis at the CIS stage is different 
than the sensitivity of mammography at other invasive stages. All the studies that have 




cases are getting diagnosed at in-situ stages. Whereas the previous model (18) only 
considered progressive pre-clinical CIS, and it assumed that the sensitivity of 
mammography at diagnosis is the same for all cancer stages, whereas sensitivity at CIS can 
vary from 30-90% of specified values. Which will impact the number of cases diagnosed 
at in-situ cancer stages. So, to study the uncertainty around the CIS pathway, dwell time 
for progressive CIS, and sensitivity of mammography at the CIS stage, we will evaluate 
five different scenarios, as mentioned in table 2. These scenarios considered different 
combination of CIS progression rate, proportion of invasive cancers initiating directly in 
local stage, and mammography sensitivity in CIS stage and have already been studied by 
different studies. These scenarios serve as lower bound and upper bound for the uncertainty 
around dwell- time for CIS stage.  














1 5.22 years 0% 40% for ages over 50 
years 
28% for ages less than 50 
(44) 
2 3 months 0% 88% (57) 
3 2 years 18.9% 40% (53) 
4 15 years 18.9% 40% (53) 
 
After evaluating these five cases, a comparison will be made to understand how uncertainty 
around CIS pathways and different mammography sensitivity for CIS impact the screening 
scenarios. 




Modality specific sensitivity and specificity are the estimate of the accuracy of test 
results and depend on the technology and expertise of radiologists. As noted, earlier 
sensitivity represents the ability of screening tests to detect people with the disease (true 
positive rate), and specificity is the ability of the test to detect those without the disease 
(true negative rate). For our study, we have assumed the use of film mammography in 
developing countries. As the availability of more advanced digital mammography in 
developing countries is limited. (58) Sensitivity and specificity estimates from the breast 
cancer surveillance consortium (BCSC) suggests that mammography specific specificity 
and sensitivity data have been increasing over time, representing the advancements in 
diagnostic tools. As a result, these values might not be the same under all resource settings 
and may vary with the availability of experienced radiologists or other diagnostic measures. 
So, to study the impact of this on optimal screening scenario, we will be using 
mammography specificity and sensitivity from the 1995-1999 era to serve as a lower 
bound, to test the impact of the unavailability of the most recent technology and human 
expertise in LMICs and will compare the results with the latest technology parameters. 
4.3.4. Comparison of screening strategies of different countries 
We will be implementing above three goals for six heterogeneous disease burden 
regions- Peru (Andean Latin America), Colombia (central Latin America), Uganda (eastern 
sub-Saharan Africa), Philippines (southeast Asia), India (south Asia), and Kyrgyzstan 
(central Asia), and will study the how screening guidelines changes within these regions. 
We will study the relationship between disease demographics and screening guidelines, as 
suggested by the MDP model. 




To measure the outcomes of screening schedules identified by the MDP model 
following impact metrics will be considered.  
• Estimation of impact metrics by Markov process simulation: For each optimal strategy, 
by simulating the Markov process model over a 100-year period, we calculated 





           




             
Costs per 1000 women = 
103(𝑐𝑠𝑐𝑟𝑒𝑒𝑛𝑁𝑠𝑐𝑟𝑒𝑒𝑛𝑠+𝑐𝐹𝑃𝑁𝐹𝑃+ 𝑐𝑇𝑃𝑁𝑇𝑃+ 𝑐𝐼𝑁𝐼+ 𝑐𝑇𝑁𝑇)
𝐿𝑏𝑎𝑠𝑒𝑐𝑎𝑠𝑒
𝑡𝑎𝑣𝑔⁄
                                       
Where,  
𝐿𝑝𝑜𝑙𝑖𝑐𝑦 = Life years lived in the intervention scenario (optimal screening strategy) over a 
100-year period,  
𝐿𝑏𝑎𝑠𝑒𝑐𝑎𝑠𝑒= Life years lived in the base-case (no screening) over a 100-year period,  
𝑡𝑎𝑣𝑔 = average life expectancy in Peru, thus,  
𝐿𝑝𝑜𝑙𝑖𝑐𝑦
𝑡𝑎𝑣𝑔
 is an approximation used for 
estimating the average number of women in the simulation. 
𝑐𝑠𝑐𝑟𝑒𝑒𝑛 is the unit cost of mammography screening, 
𝑐𝐹𝑃 is the cost per person for follow-up diagnostic tests for a false positive case, 
𝑐𝑇𝑃 is the cost per person for follow-up diagnostic tests for a true positive case, 




𝑐𝑇 is the terminal treatment cost per person, which was applied at the final 12 months of 
life for women who die of breast cancer,  
𝑁𝑠𝑐𝑟𝑒𝑒𝑛𝑠 is the total number of women who were screened over a 100-year period,  
𝑁𝐹𝑃 is the total number of false positives over a 100-year period, 
𝑁𝑇𝑃 is the total number of true positives over a 100-year period, 
𝑁𝐼 is the total number of women diagnosed with breast cancer over a 100-year period, 
and 
𝑁𝑇 is the total number of women who die of breast cancer over a 100-year period.  
• Estimation of resource (mammography machine) required: For each optimal scenario, we 
calculated the number of mammography machines needed per year as the number of 
screens per year divided by capacity of each mammography machine. We calculated the 
number of screens per year by adding the number of people in specific country in 2017 in 
the ages corresponding to the screening schedules. We assume an annual capacity of 5800 
tests per mammography machine based on current utilization in some HICs.(63) 
• Generation of efficient frontier: By plotting life-years saved versus number of lifetime 
screens and life-years saved versus costs, we generate “efficient frontier” curves to identify 
non-dominated scenarios. A scenario is non-dominated if it has the highest life-years saved 
among all scenarios with similar costs, and thus will lie on the efficient frontier.  




For validating the MDP model, it was applied to the United States (US) population 
for comparison with results from the CISNET (The Breast Cancer Working Group of the 
Cancer Intervention and Surveillance Modeling  Network (9)) study, a  study  that  used  6  
independent  models  to inform  current  screening guidelines globally.(64) Data for model 
parameterization were extracted from the CISNET studies and are presented in the 
Appendix (Table 10 and 11).  For validation following two sets of validation were 
conducted. 
Validation of impact estimates: Unlike the MDP method that identifies optimal 
schedules, the method used in the CISNET study is comparative analysis of a few pre-
selected screening schedules.(9) These pre-selected schedules were evaluated using MDP 
model and impact measures were extracted. The estimation of benefits and harms, life-
years (LY) saved per 1000 women and false positives per 1000 women, respectively, under 
different screening schedules compared well with CISNET model results (Figure 3). (9) 
We also plotted efficient frontier for these screening scenarios by plotting LY saved against 
number of lifetime screen and compared our results with that of CISNET model results. 
The scenarios identified as non-dominated in MDP model are also classified as efficient or 
borderline in the CISNET study (Figure 4). The CISNET study classified a scenario as 
‘efficient’ if it was non-dominated in at least 5 models and as ‘borderline’ if it was 
dominated in 2 to 4 models. 
Validation of the MDP method of selecting optimal schedules: To demonstrate the 
advantage of using the MDP model to identify an ‘optimal’ screening schedule, instead of 
using pre-selected schedules as commonly done, we applied the MDP model to the US 




combined the optimal schedules identified by the MDP model and the CISNET pre-
selected schedules to generate an efficient frontier by plotting life-years saved per 1000 
women against number of lifetime screens, and life-years saved per 1000 women against 
costs per 1000 women (Figure 5).  
There are two notable results from this comparison, First, all the screening 
schedules identified as optimal by the MDP model are either on or close to the efficient 
frontier curve, demonstrating that the MDP model can identify the most efficient strategies. 
Second, the MDP model helps identify the minimum number of lifetime screens, for the 
US it suggests a minimum of 10. We verify the validity of this result by using our model 
to specifically evaluate and compare cost per life-year saved under 10 lifetime screens with 
that of lower number of lifetime screens. The schedule with 10 lifetime screens had a lower 







Figure 3 Model validation on the US population: Comparing benefits (life years saved per 
1000 women) and harms (false positives) between our model (UMass) and CISNET model 
estimations. The x-axis presents the different screening strategies, biennial (B) or annual 
(A), and ages to screen. CISNET model group abbreviations: D = Dana-Farber Cancer 
Institute; E = Erasmus Medical Center; G = Georgetown University; M = M.D. Anderson 





Figure 4: Comparing efficiency frontiers from our model with 3 CISNET models for pre-
selected scenarios evaluated in the CISNET study for the US population.  
Figure legend: In the CISNET study, the screening schedules with red full circles were 
categorized as efficient (non-dominated in at least 5 CISNET models), scenarios in green 
diamond were categorized as borderline (dominated in 2-4 models), and the scenarios in 
blue “cross” were categorized as inefficient (dominated in all the models); Model Group 
Abbreviations: D (Dana Farber Cancer Center), E (Erasmus Medical Center), G 








Figure 5 : Efficiency frontier plotted by combining pre-selected scenarios in CISNET study 










































0 NA NA reference reference 3,730,421 reference reference 
5 (B60-69) 60-69 388 49 69.23491 4,618,171 18,254 12,830 
8 (B55-69) 55-69 636 85 114.9399 5,227,876 17,630 13,028 
10 47-68 841 132 167.7138 5,710,988 15,099 11,806 
11 45-68 931 142 180.5029 5,963,972 15,775 12,374 
12 44-68 1022 152 190.8303 6,225,760 16,424 13,072 
13 43-68 1097 158 197.9314 6,443,835 17,220 13,705 
14 41-68 1190 165 205.5111 6,720,099 18,111 14,543 
15 41-69 1264 168 209.3046 6,938,201 19,143 15,321 
16 41-69 1349 173 215.6531 7,195,497 20,000 16,062 
17 42-69 1437 177 220.4828 7,427,262 20,842 16,761 
18 40-69 1513 181 224.1628 7,681,212 21,887 17,618 
19 40-69 1600 185 229.3496 7,952,445 22,857 18,440 








In this section we will discuss the results for Peru, Colombia, Philippines, India, Uganda, 
Kyrgyzstan for base case i.e. for initially developed MDP model, for overdiagnosis, 
uncertainty around disease pathways and mammography sensitivity of CIS, and 
unavailability of latest technology and human expertise in LMICs. We have discussed the 
different optimal screening scenarios for all these cases for which we have plotted 
histograms for given number of lifetime screens. These histograms represent frequency of 
lifetime screens in specific age-group of five years for a given number of total lifetime 
screens.  We have also compared the life years saved per 1000 women against number of 
lifetime screens and life years saved per 1000 women against cost per 1000 women. These 
results are discussed in detail in following sections. 
5.1. Results of base case  
In this section we will discuss the results for Peru, Colombia, Philippines, India, Uganda, 
Kyrgyzstan in previous chapter for base case i.e. for initially developed MDP model. 
Figure 6 plots histograms for optimal age group to screen under choices of lifetime screens 
for all countries and also plots LY saved per 1000 women for number of lifetime screens, 
and LY saved per 1000 women for cost per 1000 women.   
For one lifetime screen, model suggests to have screening in age group 50-55 
except for Colombia. Colombia has screening at delayed age as model suggests to screen 




same life expectancy (around 76), but Colombia has delayed initiation of incidence as 
compared Peru which could be reason for the delayed screening. 
For three lifetime screens, when we increase number of lifetime screens from 1 to 
3 for all countries model suggests to screen between age group 45-60 except Colombia 
where it suggests to screen age group 50-65. If we compare Colombia to Peru as they both 
have same Life expectancy and incidence are also somewhat similar, but the only 
difference is delayed initiation of incidence for Colombia as compared to Peru. As for age 
group 40-45 incidence starts of as 0.5 in Colombia whereas it is 0.7 in Peru and similarly 
for age group 45-50 it is 0.9 in Peru and 0.8 in Colombia. So, this explains the delayed 
starting age of screening in Colombia.  
When we further increase the number of lifetime screens to five, for Peru model 
suggests to screen once in every five years age group between age 40-65 but for Colombia 
and Philippines it suggests to screen between age group 45-65 with two number of lifetime 
screens for age group 50-55. This could be due to higher incidence for age group 50-55 for 
both Colombia and Philippines as compared to age group 40-45. For both Colombia and 
Philippines incidence in age group 50-55 are around 2 times higher than age group 40-45 
whereas in Peru incidence in age group 50-55 are 1.5 time higher than age group 40-45. 
This could be the reason for screening in age group 50-55 for both Colombia and 
Philippines. For Uganda screening age group is 40-60 and for India it is 45-65 with two 
number of lifetime screens in age group 50-55 for both countries. While India and Uganda 
have similar incidence rate, younger age group of screening for Uganda as compared to 
India could be due to lower life expectancy (around age 58) of Uganda. Two number of 
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age group 50-55 is almost 2.5 times than that of age group 40-45 for Uganda and 1.9 times 
for India which is 1.6 for Kyrgyzstan and the screening interval for Kyrgyzstan is spread 
out between age group 40-65. Kyrgyzstan’s overall magnitude of incidence is small. 
For seven number of lifetime screens screening age interval for all countries is between 
age group 40-65 with at least one lifetime screen in every 5-year age group. For Peru two 
additional screens are distributed for age group 45-55 whereas for Colombia and 
Philippines it is distributed for age group 50-60 which could be due to higher incidence for 
this age group as compared to younger age group in both Colombia and Philippines as 
compared to that of Peru which is consistent with observation with one, three and five 
number of lifetime screens.  For Uganda additional screenings are added to age group 40-
45 and 60-65.  It can be explained as life years (LY) saved increases until 5 number of 
lifetime screens but after that it almost becomes steady i.e. not increasing as much. So, 
additional number of screens are just built on what we have for five number of lifetime 
screens.  




LY saved vs 
cost per 1000 
women 
   
Figure 6: Histograms for optimal screening age group for base case of all countries for 
given number of lifetime screens, LY saved per 1000 women for number of lifetime 






Similarly, for India, additional screening is added to age group 45-50 and 55-60.  If 
we compare LY saved by seven number of lifetime screens with that of five number of 
lifetime screens there is not much significant gain. So, it just picked younger age groups to 
screen for seven number of lifetime screens as compared to 5 number of lifetime screens. 
For Kyrgyzstan, additional screening is added to age group 45-55. Kyrgyzstan has higher 
incidence for age group 50-55 as compared to younger as groups as well as older age 
groups. 
As we further increase number of lifetime screens to nine and ten, additional 
screens are added to what we already have. For countries that have higher life expectancy 
like Peru, Colombia, Philippines, and Kyrgyzstan additional screens are added to the 
middle age groups (45-55) and older age groups (55-65) except Kyrgyzstan as additional 
screens are distributed towards younger and middle age groups because of low incidence 
rates in Kyrgyzstan in older ages. For Uganda and India additional lifetime screens are 
added in younger and middle age groups because of low life expectancy of both countries 
and additional lifetime screens does not increase LY saved as much after five number of 
lifetime screens and become steady after seven number of lifetime screens and these 
observations are consistent with observations for seven number of lifetime screens. These 
results also show that countries with higher incidence rates have higher benefits i.e. higher 
life-years saved per 1000 women and higher cost per 1000 women. The estimates for false 
positives per 1000 women are equivalent for all the countries because of similar assumptions for 
screening specificity. (Table 3) 
For implementing current screening guidelines in Peru i.e. screening biennially 




need approximately 280 mammograph units (Table 4). Currently there are only 55 
mammography machines available in public hospitals in Peru and with this capacity it can 
only implement 2 number of lifetime screens. For implementing current guidelines in 
Philippines i.e. screening triennially women in age group 50-69 which corresponds to 7 
number of lifetime screens, it would need approximately 575 mammograph units. But 
currently Philippines only has 79 mammography machines and can only implement 1 
lifetime screening. (Table 4) Similarly, Kyrgyzstan needs 21 mammography machines to 
implement current screening guidelines of screening triennially women in age group 50-
60, but it only has 6 mammograph units and can only implement 1 lifetime screen. (Table 
4) Uganda and India does not have national level mammography screening guidelines but 
with current capacity of 5 mammography machines Uganda can implement 1 lifetime 
screen. Number of mammography machines available in India and Colombia is unknown 
however to implement 1 lifetime screening they would need around 1060 and 50 
mammograph machines, respectively.  
Table 4  : Summary of benefits, harms, and mammography machines required under 
alternative screening schedules 

















































1 29 19 143 50 22 129 80 19 122 
2 54 31 220 102 39 221 164 36 209 
3 83 44 315 146 50 300 245 48 297 
4 109 54 395 196 63 394 323 59 373 
5 136 62 489 245 73 484 403 68 457 
6 163 70 579 301 82 581 486 76 547 




8 219 84 766 409 96 758 682 93 731 
9 243 88 842 454 103 847 751 98 811 
10 278 95 939 501 107 891 825 101 843 






















































1 18 8 95 6 13 128 1,060 10 116 
2 36 14 165 11 24 219 2,125 17 196 
3 58 20 235 15 32 310 3,287 23 281 
4 79 25 306 21 41 402 4,353 29 353 
5 103 29 376 26 47 487 5,414 33 432 
6 119 32 436 31 52 576 6,655 38 519 
7 145 36 508 36 58 672 7,829 42 604 
8 166 39 579 43 62 763 8,895 45 684 
9 182 40 643 47 66 857 10,094 48 767 
10 205 43 674 52 67 895 11,092 49 795 
 
5.2. Results of overdiagnosis 
In this section we will discuss the results after including non-progressive CIS in the 
previously developed MDP model. Including non- progressive CIS had minimal impact on 
age-interval to screening. For all countries, the screening age-group is same as that of base 
case after including overdiagnosis for all number of lifetime screens. Also, LY saved, and 
false positives did not change for all number of lifetime screens. However, quality adjusted 
life years lived decreased after adding overdiagnosis and also cost per 1000 women got 
increased as more new cases are detected at CIS stage which decreased the quality of life 







Figure 7: QALYS lived against number of lifetime screens for overdiagnosis and base case 
 
5.3. Results of uncertainty in disease pathways and mammography sensitivity of CIS  
In this section we will discuss the results of uncertainty in disease pathway and 
mammography sensitivity for CIS. Uncertainty around CIS pathway and sensitivity of CIS 
had an impact on screening schedules as discussed in this section. We note the observations 
between countries under each uncertainty case, and also note how they compare to the base 
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Figure 8 : Histograms for optimal screening age group for all countries for given number 
of lifetime screens for CIS cases for Peru 
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Figure 9 : Histograms for optimal screening age group for all countries for given number 
of lifetime screens for CIS cases for Colombia 
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Figure 10 : Histograms for optimal screening age group for all countries for given number 
of lifetime screens for CIS cases for Philippines 
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Figure 11: Histograms for optimal screening age group for all countries for given number 
of lifetime screens for CIS cases for Uganda 
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Figure 12 : Histograms for optimal screening age group for all countries for given number 
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Figure 13 : Histograms for optimal screening age group for all countries for given number 
of lifetime screens for CIS cases for India 
5.3.1. Results for CIS case 1 
 In this scenario, the dwell time for CIS stage was the same as that of base case but 
sensitivity to mammography screening for this stage was almost half of that of base case.  
• One-lifetime screen 
➢ Observations between countries: If only one lifetime screen would be adopted, the 
model suggests to screen between age 50-55 for all countries.  
➢ Observations compared to the base case: These results are same as that of base case for 
all countries except Colombia. For Colombia, baes case suggests to screen between age 
group 55-60. 
➢ Discuss difference between countries: No difference between screening across 
countries. 
➢ Discuss differences with Base case: These results were same as that of base case for all 
countries except Colombia where it moved towards younger age group which could be 
because of low sensitivity of mammography at CIS stage. 




➢ Observations between countries: If three lifetime screens were to be adopted, the model 
suggests to screen twice in age-group 50 to 55 and one time in age 55 to 60 for Peru, 
Columbia, Kyrgyzstan, and India. For Philippines it suggests to screen one time each 
in age groups 50-55, 55-60, and 60-65. For Uganda it suggests to screen one time each 
in age groups 45-50, 50-55, and 55-60.  
➢ Observations compared to the base case: In Base case, screening initiated at a younger 
age, specifically, one screen in age group 45-50, 50-55, and 55-60. 
➢ Discuss difference between countries: The shift in Philippines towards older age could 
be because of higher rate of increase in incidence for Philippines in the older age group. 
Younger age group of screening for Uganda could be due to lower life expectancy 
(average of 58 years). 
➢ Discuss differences with Base case: The shift to older age could be because of the low 
sensitivity for diagnosis of the first stage CIS. Low sensitivity of mammography means 
lower ability of technology to detect cancer at CIS stage which could result in delay 
screening. 
• Five-lifetime screens 
➢ Observations between countries: If five lifetime screens were to be adopted, the model 
suggests to screen twice in age group 50-55 and one time each in age groups 45-50, 55-
60 and 60-65 for all countries except Uganda. For Uganda it suggests to screen twice 
in age-group 55-60 and one time each in age groups 40-45, 45-50 and 50-55. 
➢ Observations compared to the base case: In base case, screening interval for Colombia, 
Philippines, and India is same as that of CIS case 1 results. For Peru and Kyrgyzstan, 




50, 50-55, 55-60 and 60-65. For Uganda, it suggests to screen twice in younger age 
group 50-55 and one time in age groups 40-45, 45-50 and 55-60. 
➢ Discuss difference between countries: Younger age group to screen in Uganda could 
be due to lower life expectancy of the country. 
➢ Discuss differences with base case: The shift to older age could be because of the low 
sensitivity for diagnosis of the first stage CIS. Low sensitivity of mammography means 
lower ability of technology to detect cancer at CIS stage which could result in delay 
screening. 
5.3.2. Results for CIS case 2 
In this scenario, dwell time for CIS stage is very low (3 months) and sensitivity to 
mammography screening for this stage is about the same as that of base case.  
• One-lifetime screen 
➢ Observations between countries: If only one lifetime screen would be adopted, the 
model suggests to screen between age group 60-65 for Peru, Colombia, and Philippines. 
For Uganda it suggests to screen between age group 55-60 and for both Kyrgyzstan 
and India it suggests to screen between age group 50-55. 
➢ Observations compared to the base case: In base case, for Peru, Philippines and Uganda 
screening was suggested at younger age group, 50-55 and for Colombia it suggests to 
screen in age group 55-60. Whereas base case results are same as that of CIS case 2 
results for both Kyrgyzstan and India. 
➢ Discuss difference between countries: Older age group to screen for Peru, Colombia 
and Philippines could be due to higher life expectancy and higher incidence rate in 




screen for Uganda as compared to India could be due to higher incidence rate in Uganda 
at older age group as compared India.  
➢ Discuss differences with base case: The shift to older age-groups in countries could be 
due to lower dwell time of CIS stage. 
• Three-lifetime screens 
➢ Observations between countries: If three lifetime screens were to be adopted, the model 
suggests to screen one time each in age groups 50-55, 55-60 and 60-65 for all countries. 
➢ Observations compared to the base case: In base case model suggests to screen younger 
age groups with screening one time each in age groups 45-50, 50-55 and 55-60 for all 
countries except Colombia for which screening interval is same as that of CIS case. 
➢ Discuss difference between countries: No difference between screening across 
countries. 
➢ Discuss differences with Base case: The shift to older age-groups in countries could be 
due to lower dwell time of CIS stage. 
• Five-lifetime screens 
➢ Observations between countries: If five lifetime screens were to be adopted, the model 
suggests to screen twice in age group 50-55 and one time each in age group 55-60, 60-
65 and 65-70 for Peru, Colombia, and Philippines. For Uganda, the model suggests to 
screen twice in age group 55-60 and one time each in age group 45-50, 50-55 and 60-
65. For Kyrgyzstan, it suggests to screen twice in age group 50-55 and one time each 
in age group 45-50, 55-60 and 60-65. For India, it suggests to screen twice in age groups 




➢ Observations compared to the base case: In base case, the model suggests to start 
screening at younger age group for Colombia and Philippines with screening one time 
each in age group 45-50, 55-60 and 60-65 and screening twice in age group 50-55 same 
as that of above results. For Peru and Kyrgyzstan, it suggests to start screening at 
younger age group with screening one time each in age group 40-45, 45-50, 50-55, 55-
60 and 60-65. For Uganda, it suggests to start screening at younger age group with 
screening one time each in age group 40-45, 45-50 and 55-60 and screening twice in 
age group 50-55. For India, it also suggests to start screening at younger age group with 
screening one time each in age group 45-50, 55-60 and 60-65 and screening twice in 
age group 50-55. 
➢ Discuss difference between countries: Lower starting age of screening for Uganda as 
compared to India, while both countries have similar incidence could be due to lower 
life expectancy of Uganda (average of 58 years). Older ending age of screening for 
Peru, Colombia and Philippines could be due to longer life expectancy. 
➢ Discuss differences with Base case: The shift to older age-groups in countries could be 
due to lower dwell time of CIS stage, i.e. faster progression to invasive cancer. 
5.3.3. Results for CIS case 3  
In this scenario, dwell time for CIS stage is 2 years less than that of base case (5.22 years) 
and it assumed that 18.9% of cancer cases initiated directly at local stage as compared to 
0% in base case, and mammography sensitivity for CIS stage is about half of that in base 
case.  




➢ Observations between countries: If only one lifetime screen would be adopted, the 
model suggests to screen between age group 50-55 for all countries except Colombia. 
For Colombia it suggests to screen between age-group 55-60. 
➢ Observations compared to the base case: Results are in consistence with base case. 
➢ Discuss difference between countries: all countries have similar age group to screen 
except Colombia. It has screening at delayed age. This can be explained by comparing 
Colombia and Peru as they have same Life expectancy, but Colombia has delayed 
initiation of incidence as compared Peru which could be reason for the delayed 
screening. 
➢ Discuss differences with Base case: Results are in consistence with base case. 
• Three-lifetime screens 
➢ Observations between countries: If only three lifetime screens would be adopted, the 
model suggests to screen one time each in age groups 50-55, 55-60 and 60-65 for all 
countries. 
➢ Observations compared to the base case: In base case model suggests to screen younger 
age groups with screening one time each in age groups 45-50, 50-55 and 55-60 for all 
countries except Colombia for which screening interval is same as that of CIS case.  
➢ Discuss difference between countries: No difference between countries.  
➢ Discuss differences with Base case: The shift towards older age group could be due to 
lower dwell time in CIS stage and lower mammography sensitivity in CIS stage. 
• Five-lifetime screens 
➢ Observations between countries: If five lifetime screens were to be adopted, the model 




for Peru, Colombia, Philippines, and India. For Uganda and Kyrgyzstan, it suggests to 
screen twice in age group 50-55 and one time each in age group 45-50, 55-60 and 60-
65.  
➢ Observations compared to the base case: In base case, for Colombia and Philippines 
the model suggests to start screening at younger age group with screening one time 
each in age group 45-50, 55-60 and 60-65 and screening twice in age group 50-55 same 
as that of above results. For Peru and Kyrgyzstan, it suggests to start screening at 
younger age group with screening one time each in age group 40-45, 45-50, 50-55, 55-
60 and 60-65. For Uganda, it suggests to start screening at younger age group with 
screening one time each in age group 40-45, 45-50 and 55-60 and screening twice in 
age group 50-55. For India, it also suggests to start screening at younger age group with 
screening one time each in age group 45-50, 55-60 and 60-65 and screening twice in 
age group 50-55. 
➢ Discuss difference between countries: Younger starting age of screening for Uganda 
could be due to lower life expectancy and for Kyrgyzstan could be due to lower 
incidence rate.  
➢ Discuss differences with Base case: The shift to older age-groups in countries is due to 
lower dwell time of CIS stage.  
5.3.4. Results for CIS case 4 
In this case dwell time for CIS stage is 15 years which is 5.22 years in base case and it 
assumed that 18.9% of cancer cases initiated directly at local stage as compared to 0% in 
base case, and mammography sensitivity for CIS stage is about half of that in base case.  




➢ Observations between countries: If only one lifetime screen would be adopted, the 
model suggests to screen between age group 45-50 for Peru, Philippines, and Uganda. 
For Colombia, Kyrgyzstan, and India it suggests to screen between age group 50-55. 
➢ Observations compared to the base case: In base case model suggests to screen older 
age group 50-55 for Peru, Philippines, and Uganda and age group 55-60 for Colombia. 
For India, age group to screen is same as that of mentioned above.  
➢ Discuss difference between countries: Younger age group to screen for Peru and 
Philippines can be explained by comparing these to Colombia as they have similar life 
expectancy, but Colombia has delayed initiation of incidence which moves screening 
age for Colombia towards older age group . Younger age group to screen for Uganda 
can be explained by comparing it to India. Both have similar incidence but as Uganda 
has lower life expectancy.  
➢ Discuss differences with base case: Younger age group to screen could be due to longer 
dwell time in CIS stage as cancer at older age groups might not progress to invasive 
cancer stages. 
• Three-lifetime screens 
➢ Observations between countries: If only three lifetime screens would be adopted, the 
model suggests to screen one time each in age groups 40-45, 45-50 and 50-55 for Peru, 
Philippines, and Uganda. For Colombia, it suggests to screen one time each in age 
group 40-45, 50-55 and 55-60. For Kyrgyzstan, it suggests to screen one time each in 
age group 45-50, 50-55 and 55-60. For India, it suggests to screen twice in age group 




➢ Observations compared to the base case:  In base case, model suggests to screen older 
age groups with screening one time each in age group 45-50, 50-55 and 55-60 for all 
countries except Colombia. For Colombia it suggests to screen older age groups with 
screening one time each in age group 50-55, 55-60 and 60-65. 
➢ Discuss difference between countries: screening older age group 55-60 in Colombia as 
could be due to delayed initiation of incidence in Colombia as compared to Peru. 
Starting screening at older age group for both India and Kyrgyzstan as compared to 
Uganda could be due to higher life expectancy of both the countries (average of 69 for 
India and 73 for Kyrgyzstan) as compared to Uganda (average of 58). 
➢ Discuss differences with Base case: Younger age group to screen could be due to longer 
dwell time in CIS stage as cancer at older age groups might not progress to invasive 
cancer stages. 
• Five-lifetime screens 
➢ Observations between countries: If only five lifetime screens would be adopted, the 
model suggests to screen twice in age groups 45-50 and 50-55 for both Peru and 
Colombia and one time in age group 40-45 for Peru and 55-60 for Colombia. For 
Philippines, it suggests to screen twice in age group 45-50 and one time in age group 
40-45, 50-55, and 55-60. For Uganda, it suggests to screen twice in age groups 40-45 
and 50-55 and one time in age group 45-50. For Kyrgyzstan and India, it suggests to 
screen twice in age group 50-55 and one time in age groups 40-45, 45-50 and 55-60. 
➢ Observations compared to the base case: In base case, for Peru and Colombia model 
suggest to start screening at same age as CIS case 4 but suggests to stop screening at 




60 and 60-65 and screening twice in age group 50-55. For Philippines, screening is 
towards older age group i.e. screening one time each in age group 45-50, 55-60 and 60-
65 and screening twice in age group 50-55. For Uganda and Kyrgyzstan, screening in 
base case starts at same age group as CIS case 4 but it ends at older age groups. For 
Uganda, it suggests to screen one time each in age group 40-45, 45-50 and 55-60 and 
screening twice in age group 50-55. For Peru and Kyrgyzstan, it suggests to screen one 
time each in age group 40-45, 45-50, 50-55, 55-60 and 60-65. For India, in base case 
screening starts at older age group and end at older age group i.e. to screen one time 
each in age group 45-50, 55-60 and 60-65 and screening twice in age group 50-55. 
➢ Discuss difference between countries: Delayed screening in Colombia could be due to 
delayed initiation of incidence in Colombia as compared to Peru. Early ending of 
screening for Uganda as compared to India and Kyrgyzstan could be due to its lower 
life expectancy of Uganda.  
➢ Discuss differences with base case: Younger age group to screen could be due to longer 
dwell time in CIS stage as cancer at older age groups might not progress to invasive 
cancer stages. 
The uncertainty in CIS pathways discussed in cases 1 to 5 have minimal impact on cost 
per 1000 women but have significant impact on LY saved per 1000 women. All the dwell 
times cases have lower LY saved as compared to base case with case 2 having the lowest 
life years saved.   
5.3.5. Results for Uncertainty analysis on US 
We also analyzed the impact of uncertainty of CIS disease pathway and sensitivity of 




minimum of 10 lifetime screens for US. Case 1, which has similar dwell time as that of 
base case but sensitivity of mammography is half of that of base case suggests minimum 
of 7 lifetime screens. Case 2, which has least dwell time among all cases suggests minimum 
of 2 lifetime screens. As Case 3 creates similar setting to that of case 2 it suggests minimum 
of 3 lifetime screens. Case 4 which has longest dwell time suggests to have minimum of 8 
lifetime screens.  (Figure 14) 
For case 1, model suggests starting of screening in age group 50 and ending of screening 
is age group 70 for both 7 and 8 number of lifetime screens. For case 2 and 3, model 
suggests to screen older age groups for 3 lifetime screens starting from age group 60 and 
ending at age group 75 and move towards younger age groups as the number of screening 
increases while the ending age-group of screening still being at age group 75. In case 5, as 
observed in other countries screening interval moved towards younger age group with 
starting age group of screening being 45 and ending age group being 65 for 8 number of 
lifetime screens. (Figure 14)  
 For US, all these cases suggest to start screening at older age group as compared to 
LMICs which could be due to higher incidence rate in the US and higher life-expectancy 




Figure 14 : Histograms for optimal screening age group for all countries for given number 
of lifetime screens for CIS cases for the US 
5.4. Results for impact of delays in availability of latest technology and human 
expertise 
In this section, we will discuss results related to impact of delay in availability of latest 
technology and human expertise.  
To study the impact of unavailability of latest technology and human expertise in LMICs 
we used the old sensitivity and specificity data from 1995-1999 era. Using older sensitivity 
and specificity of film mammography, compared to base case, had minimal impact on age-
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and specificity data to that of base case for all number of lifetime screens. However, under 
any given number of lifetime screens, it reduced life-years saved and increased false 
positives. (Figure 15)  
   
   
   
   
   
   
Figure 15: Life years saved per 1000 women against number of lifetime screens presented 
in first row, Life years saved per 1000 women against cost per 1000 women presented in 
second row, False positives per 1000 women against number of lifetime screens presented 





DISCUSSION AND CONCLUSIONS 
6.1. Discussion 
This thesis used MDP model to suggest optimal screening schedules for breast 
cancer for LMICs. Implementing MDP model to different LMICs with different disease 
burden and life- expectancy suggests that optimal screening scenarios for country might be 
different. For instance, if countries have same life-expectancy and different disease burden, 
model suggests to screen age groups with higher incidence rates. For example, both 
Colombia and Peru have similar life-expectancy, but Colombia has delayed initiation of 
incidence thus model suggests delayed screening in Colombia as compared to Peru. It 
suggests to screen more frequently in the age groups with higher incidence rates as 
compared to other age groups. For countries with similar incidence rate and different life 
expectancy model suggests to screen younger age groups for countries with lower life-
expectancy. For instance, India and Uganda have similar incidence rate whereas Uganda 
has much lower life-expectancy than India and for five number of lifetime screens model 
suggests to start screening at age 40 for Uganda where as it suggests to start screening at 
age 45 for India. 
Results for optimal screening schedules under alternative constraints on the number 
of lifetime screens are especially of interest with respect to resource availabilities and 
population’s compliance to screening. For instance, Peru currently has about 55 
mammography machines nationally in public hospitals. (59, 63) The results indicate that, 
assuming 100% compliance, this would be sufficient for implementing 2 lifetime screens 




Philippines has only 79 mammography machines nationally available (61) and with these 
resources, as per our results only 1 lifetime screen, assuming 100% compliance, at age 54 
can be implemented in the country. Similarly, in Kyrgyzstan as well only 1 lifetime screen 
at age 54, with 100% compliance, can be implemented with current resources as the 
country has only 6 mammography machines in both public and private sectors. (61) 
Uganda only has 5 mammography machines available in the country (61) and to implement 
even 1 lifetime screen country needs at least 17 mammography machines. So, they need 
additional 12 machines. Current availability of nationwide mammography machines for 
both India and Colombia is unavailable but to implement 1 lifetime screen with 100 % 
compliance, India needs 1060 and Colombia needs 50 mammography machines. The 
results for the model are helpful for planning health investments in the country i.e. if 
countries want to implement a greater number of lifetime screens, they can invest 
accordingly to increase their current capacity. 
 After incorporating overdiagnosis in the MDP model, the optimal screening 
scenarios did not change for any of the country. There are no additional benefits of 
including this to our model. Overdiagnosis had an impact on cost per 1000 women, which 
got increased as additional treatment cost is added for the new diagnosed cases. This 
increase in cost per 1000 women is less than 1% and hence not significant.  
CIS cases have most impact on screening age interval. CIS case 1 and base case 
both has same progression for CIS stage but different sensitivity for CIS. Which resulted 
in delay of screening because availability of technology to detect CIS is low in CIS case 1.  
In CIS 2, where dwell for CIS stage is much lower than base case suggested to screen older 




less. As a result, this case has lowest life years saved as compared to other cases and base 
case.  Case 3, which creates a similar setting as Case 2 because of a combination of short 
dwell time, low mammography sensitivity, and a fraction of cases starting directly as 
invasive cancer resulted in moving screening towards older age groups as well. Case 4 
which has the longest dwell time resulted in moving screening age towards younger age 
and cut-offs screening at age 60 as screening after age 60 will have little impact as cancer 
originating after this age might not develop to invasive cancer in women’s lifetime. 
Analyzing these results suggests that disease pathways and progression plays an important 
part in suggesting screening recommendations and these parameters should be evaluated 
before developing guidelines for a specific disease burden region. 
Evaluating screening scenarios if advanced technology and human expertise is 
unavailable has minimal impact on screening age. It only affected the benefits, harms, and 
total costs.  
6.2. Summary  
In summary for Peru, for 1 lifetime screen model suggests to screen between age 
group 50-55 for base case, case 1 and case 3 whereas it suggests to screen older age-group 
60-65 for case 2 and younger age group 45-50 for case 4. For 3 number of lifetime screens 
model suggests to screen between age group 45-60 for base case, age group 50-65 for both 
case 2 and case 3, and age group 40-55 for case 4 with one screening in each age group of 
five years whereas for case 1 it suggests to screen twice in age group 50-55 and once in 




For Colombia, for 1 lifetime screen model suggests to screen between age group 
55-60 for base case and case 3 whereas it suggests to screen older age-group 60-65 for case 
2 and younger age group 50-55 for both case 1 and case 4. For 3 number of lifetime screens 
model suggests to screen between age group 50-65 for base case, case 2 and case 3, and 
age group 40-45 and 50-60 for case 4 with one screen in each age group of five years 
whereas case 1 suggests to screen twice in age group 50-55 and once in age group 55-60. 
For Philippines, for 1 lifetime screen model suggests to screen between age group 
50-55 for base case, case 1 and case 3 whereas it suggests to screen older age-group 60-65 
for case 2 and younger age group 45-50 for case 4. For 3 number of lifetime screens model 
suggests to screen between age group 45-60 for base case, age group 50-65 for case 1, case 
2 and case 3, and age group 40-55 for case 4 with one screen in each age group of five 
years. 
For Uganda, for 1 lifetime screen model suggests to screen between age group 50-
55 for base case, case 1 and case 3. Whereas it suggests to screen age-group 55-60 for case 
2 and younger age group 45-50 for case 4. For 3 number of lifetime screens model suggests 
to screen between age group 45-60 for base case and case 1, age group 50-65 for case 2 
and 3, and age group 40-55 for case 4 with one screen in each age group of five years. 
For Kyrgyzstan, for 1 lifetime screen model suggests to screen between age group 
50-55 for base case and all other uncertainty cases. For 3 number of lifetime screens model 
suggests to screen between age group 45-60 for base case and case 4, age group 50-65 for 
case 2 and case 3 with one screen in each age group of five years whereas for case 1 it 




For India, for 1 lifetime screen model suggests to screen between age group 50-55 
for base case and all other uncertainty cases. For 3 number of lifetime screens model 
suggests to screen between age group 45-60 for base case, age group 50-65 for case 2 and 
case 3 with one screening in each age group of five years whereas it suggests to screen 
twice in age group 50-55 for both case 1 and case 4 but suggests to screen once in age 
group 55-60 for case 1 and age group 45-50 for case 4. 
6.3.  Limitations 
The model in subject to some limitations. We only considered heterogeneity by age 
for incidence and did not consider any other causal factors such as diet, alcohol and tobacco 
consumption, or genetics. For women who were diagnosed, we did not explicitly model 
recurrence of disease, we only applied an average stage-and-age-specific rate of survival. 
We assumed that all women diagnosed with the disease receive treatment and, upon disease 
onset, its natural progression in preclinical stages only vary by age and stage. We did not 
model heterogeneity in cancer subtypes between different populations, or the family 
history of cancer. We did not model CIS cases that can regress and are screen detectable 
due to the unavailability of data for estimating rates specific to the country, thus our model 
did not consider the costs and disability associated with unnecessary treatment of these 
cases. This work is suitable for informing national-level mammography screening 
guidelines specific to a country and for planning infrastructure scale-ups, implementation 
of cancer control programs should be studied separately to consider the broader context of 
cancer control interventions. In construction of the model for the US for validation with 




as incidence and mortality that varied as a function of time, but only used the point 
estimates publicly available through their publications. 
6.4. Conclusions 
Despite these limitations, this thesis makes significant contribution. Insights from 
this thesis can be used by decision makers to inform policies related to cancer control based 
on disease burden of the country, all-cause mortality, pathway of disease and availability 
of resources. It can also help in informing future investment plans to scale-up the capacity 
and implementing a greater number of lifetime screens. Our model also suggests that 
uncertainty around disease pathway has an impact on screening guidelines and thus these 




APPENDIX A  
TWO-STEP MARKOV PROCESS METHODOLOGY FOR 
PARAMETRIZATION OF THE NATURAL ONSET AND PROGRESSION OF 
CANCER 
 
The parameterization methodology, developed specifically for limited-data settings 
such as LMICs where longitudinal cancer registry databases are not available, is an 
integration of two Markov processes. Technical details of the theory and proofs of the 
methodology are presented in (17) and its application for the analysis of the ‘Best Buy’ 
interventions, for breast cancer, cervical cancer, and colorectal cancer at the regional levels 
for Eastern Sub-Saharan Africa and Southeast Asia, for updating the Appendix 3 of the 
NCD Global Action Plan (65, 66) are presented in (67). Here, we only present an overview 
of the algorithm. 
 
➢ Overview of the two-step Markov processes  
 
The methodology divides the estimation of population-specific onset rates of disease 
and diagnostic rates into two steps, each defined by a Markov process model but with 
different state spaces. In the first step, we define the disease onset and progression as a 
discrete-time Markov process 𝑿 = {𝑋𝑡; 𝑡 ≥ 0,Ω, ℙ} with a collapsed state space Ω =
{[𝐻𝑎], [𝑈𝑎], [𝐷𝑎]} representing age 𝑎 and health states 𝐻𝑎  =healthy, 𝑈𝑎= undiagnosed, and 
𝐷𝑎= diagnosed, without differentiating between disease stages; and ℙ is the transition 
probability matrix. We estimate age-specific onset rates using an iterative analytical model 
derived using the Markov chain 𝑿. 
In the second step, we estimated diagnostic rates in each stage of cancer, i.e., transition 




the Markov process 𝒀 = {𝑌𝑡; 𝑡 ≥ 0, 𝑍, ℚ}, with state space 𝑍 = {[𝐻𝑎], [𝑈𝑖,𝑎], [𝐷𝑖,𝑎]}, which 
is an expansion of the state space in equation (1) to include stage 𝑖 ∈ {0 = 𝐶𝐼𝑆, 1 =
𝐿𝑜𝑐𝑎𝑙, 2 = 𝑅𝑒𝑔𝑖𝑜𝑛𝑎𝑙, 𝑎𝑛𝑑 3 = 𝐷𝑖𝑠𝑡𝑎𝑛𝑡} and age 𝑎; and rate matrix ℚ, which corresponds 
to the  flow diagram in Figure 1. 
We discuss each of these steps below.  
➢ Estimation of disease onset rates (𝜽𝒂)  
 
In this first step, for estimation of the onset rates, we define disease onset and 
progression as a discrete-time Markov process,  
𝑿 = {𝑋𝑡; 𝑡 ≥ 0,Ω,ℙ} (1) 
with a collapsed state space Ω = {[𝐻𝑎], [𝑈𝑎], [𝐷𝑎]} representing age 𝑎 and health states 𝐻𝑎  
=healthy, 𝑈𝑎= Undiagnosed, and 𝐷𝑎= diagnosed, (see Figure 16 for a flow diagram, and 
Table 7 for a list of notations), without differentiating between disease stages; and ℙ is the 
transition probability matrix. Then, using steady state Markov properties we can write 
𝜋𝑘 =∑𝜋𝑗
𝑗𝜖Ω,
𝑃𝑗𝑘   ; 0 ≤ 𝜋𝑘 ≤ 1; ∑𝜋𝑘
𝑘𝜖Ω
= 1                                                                                           (2) 
where, 𝑃𝑗𝑘 are the probabilities of transitioning from state 𝑗 to state 𝑘, i.e., elements of the 
matrix ℙ, and 𝜋𝑘 are the elements of the steady-state distribution vector 𝝅. Our prime 
element of interest in this Markov process is 𝑃𝐻𝑎𝑈𝑎 , the risk or probability of developing 
the disease in age 𝑎, i.e., an element of ℙ representing the probability of transitioning from 




underlying distributions governing transition probabilities are exponential, the rate of 
disease onset in age group 𝑎 can be written as 𝜃𝑎 = −ln (1 − 𝑃𝐻𝑎𝑈𝑎). Based on the above 














                        
(3)                     
and developed an iterative process for estimation of 𝑃𝐻𝑎𝑈𝑎  starting with the lowest age. We 
present the notations and the iterative process for estimating 𝑃𝐻𝑎𝑈𝑎and eventually 𝜃𝑎 in 
Tables 5 and 6, respectively. The details of the derivation are presented elsewhere. (17) 
 
Figure 16: Flow diagram for the collapsed state space in the Markov process used for 













Table 5 : Summary of notations for estimation of onset rates using algorithm in Table 6 
Notation Description 
Model 1: 𝑿 =
{𝑋𝑡; 𝑡 ≥ 0,
Ω, ℙ,𝝅} 
𝑿 is a Markov process with state space Ω, its underlying discrete 
time Markov chain given by the one-step transition probability 
matrix  ℙ and steady-state distribution vector 𝝅.  
[𝐻𝑎], [𝑈𝑎], [𝐷𝑎] 
Age-vectors representing states of healthy, pre-clinical disease 
(i.e., undiagnosed cancer state), and clinical disease (i.e., 
diagnosed cancer state), respectively, for age 𝑎 
𝜋𝑗 
Element of vector  𝝅 representing steady-state probability for state 
𝑗 
𝑃𝑗𝑘𝑃𝑗𝑘 
Element of the matrix ℙ representing one-step probability of 
transitioning from state 𝑗 to 𝑘  
𝑃𝐻𝑎𝑈𝑎
= 1 − 𝑒−𝜃𝑎  
𝑃𝐻𝑎𝑈𝑎  is the risk of developing disease at age 𝑎, and is defined as 
the one-step probability of transitioning from healthy to preclinical 
disease (𝐻𝑎 𝑡𝑜 𝑈𝑎); 𝜃𝑎 is the rate of disease onset per person-year 
among persons in age 𝑎 (used in Model  2) 
𝑇 
𝑇 is a random variable denoting the time taken to transition to 
clinical disease state from the time of disease onset (sojourn time); 
 𝑇~ℎ𝑦𝑝𝑒𝑟𝑒𝑥𝑝𝑜𝑛𝑒𝑛𝑡𝑖𝑎𝑙(𝜆1, 𝑠1, … , 𝜆4, 𝑠4 ), 𝑠𝑖 is the probability that 
𝑇 will take the form of the exponential distribution with rate 𝜆𝑖   
𝑆 
𝑆 is a random variable denoting time of natural survival past the 
age at disease onset (i.e., the person does not die from any other 
disease during this time);  𝑆~𝑒𝑥𝑝𝑜𝑛𝑒𝑛𝑡𝑖𝑎𝑙(𝜇𝑘) 
𝐼𝐷𝑎 
Cancer incidence, defined as the number of new cases of cancer 
diagnoses in age 𝑎 each year divided by the number of people in 
age 𝑎  
𝑐𝑎 The proportion of the total population in age 𝑎  
𝐴𝑎 
Among persons in age group 𝑎, the proportion in healthy state or 
pre-clinical disease states  
𝑝𝑖,𝑎  
Rate of progression from disease stage 𝑖 to 𝑖 + 1 (also used in 
Model 2) 
𝜇𝑎 Disease-free mortality rate at age 𝑎 
Model 2: 𝒀 =
{𝑌𝑡; 𝑡 ≥
0, Ζ, ℚ, 𝝆} 
𝒀 is a continuous time Markov process with state space Ζ, 
generator matrix ℚ, and steady state distribution vector 𝝆.  
[𝐻𝑎], [𝑈𝑖,𝑎], [𝐷𝑖,𝑎] 
Age-vector representing states of healthy, pre-clinical disease (i.e., 
undiagnosed cancer state), and clinical disease (i.e., diagnosed 









Table 6 : Overview of the algorithm for computing age-specific onset rate of cancer 
Initialize 𝜋𝐻0 = 𝐴0;  𝜋𝑈0 = 0; and 𝑃𝐻0𝑈0 = 0; Set 𝑎 = 1, the youngest age-group of 
cancer onset (we assumed age 15 for breast cancer).  
Step 1: Calculate in-situ onset rate 
𝑃𝐻𝑎𝑈𝑎
=
𝐼𝐷𝑎𝑐𝑎 −∑ (𝜋𝐻𝑘𝑃𝐻𝑘𝑈𝑘[∑ 𝑠𝑖(1 − 𝑒























Then, disease onset rate at age 𝑎 is estimated as 
𝜃𝑎 = −ln (1 − 𝑃𝐻𝑎𝑈𝑎) 



























Step 3: Increment 𝑎 by 1; if 𝑎 is less than the maximum age goes to step 1, else stop. 
 
➢ Estimation of diagnostic rates  
𝑑𝑖,𝑎 
Diagnostic rates, defined as the rates of transitioning from pre-
clinical stage 𝑖 to clinical-stage 𝑖 per person-year for persons in age 
 𝑎 
𝑝𝑖,𝑎  
Rate of progression from disease stage 𝑖 to 𝑖 + 1 (also used in 
Model 1) 
𝜇𝑎 Disease-free mortality rate at age 𝑎 
?̅?𝑖,𝑎 Mortality rates not on treatment and at disease stage 𝑖 and age 𝑎 
?̿?𝑖,𝑎 Mortality rates on treatment and at disease stage 𝑖 and age 𝑎 
𝐼𝑎 Cancer incidence by age  𝑎 




In the second step of the two-step Markov process, for estimation of diagnostic 
rates, we reformulate the discrete-time Markov process 𝑿, in previous section that defined 
disease onset and progression, into a continuous-time discrete-state Markov process 𝒀 =
{𝑌𝑡; 𝑡 ≥ 0, 𝑍,ℚ}, with more granular discretization of the state space as 𝑍 =
{[𝐻𝑎], [𝑈𝑖,𝑎], [𝐷𝑖,𝑎]}, for stage 𝑖 ∈ {0 = 𝐶𝐼𝑆, 1 = 𝐿𝑜𝑐𝑎𝑙, 2 = 𝑅𝑒𝑔𝑖𝑜𝑛𝑎𝑙, 𝑎𝑛𝑑 3 =
𝐷𝑖𝑠𝑡𝑎𝑛𝑡} and age 𝑎, and rate matrix ℚ. We estimated diagnostic rates in each stage of 
cancer, i.e., transition rates from preclinical to clinical states (𝑑𝑖,𝑎), by using a simulation-
based optimization of the Markov process 𝒀.  
The objective of the simulation-based optimization model is to minimize the sum 
of square errors between the simulated cancer incidence (𝐼?̅?) and the GLOBOCAN 
predicted incidence (𝐼𝑎). (54) The details of the model are presented in (17), which were 
applied to sub-Saharan Africa and Southeast Asia regions using data from 2008 to 2012, 
when there was not much screening in these regions. However, in the case of Peru, certain 
populations underwent screening prior to 2012. Therefore, the model was in (17) modified 
to consider this difference, which is discussed here. For completeness, we first present the 
earlier version of the model formulation before discussing the modifications specific to 
Peru. The objective function was formulated as 
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒𝑑𝑖,𝑎 ∑ (𝐼?̅? − 𝐼𝑎)𝑎
2
, 𝑑𝑖,𝑎 ≥ 0, ∀𝑖, 𝑎      
 (4) 
As the analytical form of 𝐼?̅? are unknown, we used a numerical optimization 
solution method where the objective function value can be evaluated numerically through 




specific 𝑑𝑖,𝑎 values, we simulated the Markov Process 𝒀 over time 𝑡 using 𝝆𝑡+1 = 𝝆𝑡 +
 𝝆𝑡ℚ∆𝑡 until it reached state steady, i.e., 
𝝆 =  𝝆 +  𝝆ℚ∆𝑡       
                                                                                  
(5) 
where 𝝆 is a vector of state distribution at steady state and ℚ is the rate matrix. We 
estimated 𝐼?̅? using 𝐼?̅? = ∑ 𝜌𝑈𝑖,𝑎 𝑑𝑖,𝑎𝑖 , where 𝜌𝑈𝑖,𝑎 is the steady state value for state 𝑈𝑖,𝑎 
(denoting the prevalence in pre-clinical cancer stage 𝑖 at age 𝑎), which can be estimated by 
expansion of equation (5) as 
 𝜌𝑈𝑖,𝑎 = 𝜌𝑈𝑖,𝑎 + 𝜌𝑈𝑖−1,𝑎−1𝜆𝑖−1,𝑎 − 𝜌𝑈𝑖,𝑎−1 (𝜆𝑖,𝑎 + 𝑑𝑖,𝑎 + 𝜇𝑖,𝑎)    
 (6) 
 In the previously presented model in (1), because of the assumption that diagnosis 
occurs only based on symptoms and that the probability of showing symptoms are higher 
in advanced disease stages, i.e., 𝑑𝑖,𝑎 > 𝑑𝑖−1,𝑎, the distribution of the stage at diagnosis was 






𝑗=0 , where 𝑠𝑗 is the proportion diagnosed in stage 𝑗, and 𝑑𝑖,𝑎 is the diagnostic rate at 
state 𝑖 and age 𝑎. Therefore, for the terms in the objective function in equation (4) we could 
write 
(𝐼?̅? − 𝐼𝑎)
2 = (∑ 𝜌𝑈𝑖,𝑎 𝑑𝑖,𝑎𝑖 − 𝐼𝑎)
2
= (∑ 𝜌𝑈𝑖,𝑎 (𝑑3,𝑎 ∑ 𝑠𝑗
𝑖
𝑗=0 )𝑖 − 𝐼𝑎)
2
≈  𝑓(𝑑3,𝑎)  
 (7) 
That is, the only unknown values in the objective function in equation (4) were the 




clinical states, 𝜌𝑈𝑖,𝑎, are estimated numerically from the simulation of the Markov model 
in equation (5) as discussed above. The resulting objective function was  
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒 𝑑3,𝑎 ∑ (∑ 𝜌𝑈𝑖,𝑎 (𝑑3,𝑎 ∑ 𝑠𝑗
𝑖
𝑗=0 )𝑖 − 𝐼𝑎)
2
𝑎                                                                                                
(8) and the decision variables 𝑑3,𝑎∀𝑎 were solved iteratively for each 𝑎. However, in the 
case of Peru, certain populations have undergone screening based on recommendations 
prior to 2012 (the latest incidence data available at the time of this work was for year 2012), 
and thus, the assumption 𝑑𝑖,𝑎 > 𝑑𝑖−1,𝑎 does not hold. Therefore, we modified the objective 
function in equation (7) to  
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒 𝑑𝑖,𝑎 ,∀𝑖,𝑎 ∑ (𝜌𝑈𝑖,𝑎 (𝑑𝑖,𝑎) − 𝐼𝑎)
2
𝑖,𝑎 ,𝑑𝑖,𝑎 ≥ 0,∀𝑖, 𝑎                                                                              
(9) that is, the number of decision variables (the unknown values) now increase to include 
diagnostic rates 𝑑𝑖,𝑎 for each stage 𝑖 and age 𝑎, as the actual rates of screening currently 
occurring in the population are unknown. This creates many decision variables. As the 
number of decision variables increases, ascertaining the convergence of a solution 
algorithm to the global optima becomes more challenging. We address this by showing 
below that the optimization problem in equation (9) is separable both on 𝑖 and 𝑎 and thus 
equation (9) can be converted to 𝑖 × 𝑎 number of sub-problems. Each sub-problem can 
then be solved separately but iteratively for 𝑑𝑖,𝑎, iterating over each 𝑖 and 𝑎 (see below). 
We further test for the convexity of each sub-problem (see Appendix C).  
Remark 1: We can rewrite equation (9) as,  
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒 𝑑𝑖,𝑎 (𝜌𝑈𝑖,𝑎 (𝑑𝑖,𝑎) − 𝐼𝑎)
2
,𝑑𝑖,𝑎 ≥ 0                                                                                                        




function can then be solved separately for 𝑑𝑖,𝑎 but iteratively over age 𝑎 starting from the 
youngest age and, within each age, iteratively over cancer state 𝑖 starting with the earliest 
disease state.   
Proof:  
Using the expression for 𝜌𝑈𝑖,𝑎 , from the expansion of the Markov process in 
equation (6) discussed above, and multiplying by 𝑑𝑖,𝑎 we can write 
𝜌𝑈𝑖,𝑎 𝑑𝑖,𝑎 = [𝜌𝑈𝑖,𝑎 + 𝜌𝑈𝑖−1,𝑎−1𝜆𝑖−1,𝑎 − 𝜌𝑈𝑖,𝑎−1 (𝜆𝑖,𝑎 + 𝑑𝑖,𝑎 + 𝜇𝑖,𝑎)] 𝑑𝑖,𝑎       
(11) 
In equation (8), for 𝑖 = 0 (the in-situ stage) 𝜆𝑖−1,𝑎−1 = 𝜃𝑎−1 the cancer onset rate, 
and for all other values of 𝑖 (i.e., local, regional, and distant stages) 𝜆𝑖−1,𝑎−1 are the 
progression rates (see Figure 1); and 𝜇𝑖,𝑎−1 are the mortality rates. Values for 𝜆𝑖−1,𝑎−1 and 
𝜇𝑖,𝑎−1 are known. When 𝑖 = 0 (the in-situ stage) 𝜌𝑈𝑖−1,𝑎−1 = 𝜌𝐻𝑎−1denoting the steady state 
value in healthy (i.e., prevalence of healthy stage), and under all other values of 𝑖,  𝜌𝑈𝑖−1,𝑎−1 
are the steady state values in the pre-clinical states (i.e., prevalence of pre-clinical cancer 
stages). For any given 𝑖, 𝑎 pair, from Remark 2 and its proof below, the steady state values 
for 𝜌𝑈𝑖,𝑎−1 and 𝜌𝑈𝑖−1,𝑎−1, and solution to 𝑑𝑖,𝑎−1 are known.  Therefore, for any value of 𝑑𝑖,𝑎 , 
the steady state value for 𝜌𝑈𝑖,𝑎 can be calculated through simulation of the Markov process 
in equation (5). As such, the only unknown value in equation (11) will then be 𝑑𝑖,𝑎. 
This completes the proof. 
Remark 2:  If we iteratively solve for 𝑑𝑖,𝑎 using equation (11) by iterating over 𝑎 and, 




and 𝜌𝑈𝑖−1,𝑎−1, and the solution to 𝑑𝑖,𝑎−1 are known. Thus, the only unknown term in 
equation (11) is 𝑑𝑖,𝑎 
Proof: 
We prove this by applying mathematical induction on equation (11) 
For 𝑖 = 0, 𝑎 = 1, 
𝜌𝑈0,1 𝑑0,1 = [𝜌𝑈0,1 + 𝜌𝐻0𝜃1 − 𝜌𝑈0,0 (𝜆0,𝑎 + 𝑑0,𝑎 + 𝜇𝐻,𝑎)] 𝑑0,1                                   
(12) 
Then, the only unknown value is 𝑑0,1 because 𝜌𝑈0,0 = 0 and 𝜌𝐻0  is the actual 
prevalence of healthy persons in age 0 (obtained from population demographics) as the 
first age for disease risk is 1, and all other parameters are known as discussed in proof of 
Remark 1. 
Assuming the proof holds for 𝑖 = 𝑚, 𝑎 = 1, 
for  = 𝑚 + 1 , 𝑎 = 1 
𝜌𝑈𝑚+1,1 𝑑𝑚+1,1 = [𝜌𝑈𝑚+1,1 + 𝜌𝑈𝑚,0𝜆𝑚,1 − 𝜌𝑈𝑚+1,0 (𝜆𝑚+1,1 + 𝑑𝑚+1,1 +
𝜇𝑚+1,1)] 𝑑𝑚+1,1    (13) 
Then, the only unknown parameter is 𝑑𝑚+1,1 as 𝜌𝑈𝑚,0 = 0 and 𝜌𝑈𝑚+1,0 = 0 as 
the first age of disease risk is 1.  
For = 0 , 𝑎 = 2 





Then, the only unknown parameter is 𝑑0,2 because 𝜌𝐻1 = 𝜌𝐻1 − 𝜌𝐻0(𝜃1 + 𝜇𝐻,1) 
can be estimated through steady state simulation of equation (5) and 𝜌𝑈0,1  was estimated 
previously under = 0 , 𝑎 = 1. 
Assuming the proof holds for 𝑖 = 𝑚 + 1, 𝑎 = 2, 
𝜌𝑈𝑚+1,2 𝑑𝑚+1,2 = [𝜌𝑈𝑚+1,2 + 𝜌𝑈𝑚,1𝜆𝑚,2 − 𝜌𝑈𝑚+1,1 (𝜆𝑚+1,2 + 𝑑𝑚+1,2 +
𝜇𝑚+1,2)] 𝑑𝑚+1,2   (15) 
Then, the only unknown parameter is 𝑑𝑚+1,2 as 𝜌𝑈𝑚,1 and 𝜌𝑈𝑚+1,1  were 
estimated above under = 𝑚 , 𝑎 = 1 and 𝑖 = 𝑚 + 1 , 𝑎 = 1, respectively 
Finally, assuming the proof holds for any 𝑖  and 𝑎 = 𝑘, 
for any 𝑖 , and 𝑎 = 𝑘 + 1 
𝜌𝑈𝑖,𝑘+1 𝑑𝑖,𝑘+1 = [𝜌𝑈𝑖,𝑘+1 + 𝜌𝑈𝑖−1,𝑘𝜆𝑖−1,𝑘+1 − 𝜌𝑈𝑖,𝑘 (𝜆𝑖,𝑘+1 + 𝑑𝑖,𝑘+1 + 𝜇𝑖,𝑘+1)] 𝑑𝑖,𝑘+1          
(16) 
Then, the only unknown parameter is 𝑑𝑖,𝑘+1 as 𝜌𝑈𝑖−1,𝑘  and 𝜌𝑈𝑖,𝑘  were estimated 
above under any 𝑖 and 𝑎 = 𝑘. 
This completes the proof. 
➢ Test for convexity of the optimization model for estimation of diagnostic rates 
To check for the convergence of the solution to global optima we test for the convexity 




Specifically, we test for the commonly used convexity test, a function 𝑓(𝑥) that is twice 
differentiable on 𝑥 is convex if it is positive semi-definite, i.e., the second derivative 
𝑓′′(𝑥) ≥ 0 at all points of 𝑥. However, we do not know the analytical form of 𝐼?̅?,𝑎 to 
calculate the second derivative of the objective function (𝐼?̅?,𝑎 − 𝐼𝑖,𝑎)
2
. Therefore, for each 
combination of cancer stage (𝑖) and age (𝑎) pair, we empirically generated the function 
for 𝐼?̅?,𝑎 by estimation at multiple points of 𝑑𝑖,𝑎. See Figure 17 and Figure 18 for results on 
In-situ and Local stages of cancer and at multiple age groups. 
  
  
Figure 17: Incidence vs diagnostic rate for specific age-group and In-situ stage of cancer 
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Figure 18: Incidence vs diagnostic rate for specific age-group and local stage of cancer 
From the above empirical results, for any given cancer stage and age, the 
simulated incidence 𝐼?̅?,𝑎 is approximately a linear or a logarithmic function of diagnostic 
rates 𝑑𝑖,𝑎, i.e., 
𝐼?̅?,𝑎~𝑐 𝑙𝑛(𝑑𝑖,𝑎) + 𝑏 or 𝐼?̅?,𝑎~𝑐𝑑𝑖,𝑎 + 𝑏 for some constants 𝑐 and 𝑏. 
Writing 𝑥 = 𝑑𝑖,𝑎, 
If 𝐼?̅?,𝑎~𝑐 𝑙𝑛(𝑥) + 𝑏 , the second derivative of the objective function 
(𝐼?̅?,𝑎 − 𝐼𝑖,𝑎)
2
























































(𝑐𝑥 + 𝑏 − 𝐼𝑖,𝑎)
2
= 2𝑐(𝑐) > 0                                                                                               
(18) 
thus, empirical data indicates that the objective function (𝐼?̅?,𝑎 − 𝐼𝑖,𝑎)
2
 is convex. 
➢ Transition probability matrix for the Markov decision process model  
Table 7: Notation used in transition probability matrix 
𝜃𝑖,𝑎 Onset rate of breast cancer 
𝜆𝑖,𝑎 Dwell rate for cancer stage 𝑖 and age 𝑎 
𝑑𝑖,𝑎 Diagnostic rate of cancer in stage 𝑖 and age 𝑎 
𝜇𝑎 Natural mortality rate at age 𝑎 
𝜇𝑖,𝑎̿̿ ̿̿̿ Diseased mortality in cancer stage 𝑖 and age 𝑎 



























𝑑̅𝑖,𝑎 = (1 − 𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦)𝑑𝑖,𝑎 + 𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦
− 𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦(1 − 𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦)𝑑𝑖,𝑎  
?̅?𝑖,𝑎 = (1 − 𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦)𝜆𝑖,𝑎 
𝑠 = (1 − 𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦) 
➢ Data assumptions for parameterization of cancer onset and progression 
Table 10 and 11 presents data specific to the countries that were used for constructing 
cancer onset and progression models specific to these countries using the two-step 
Markov process methodology. 
Table 10 : Region specific input data for parameterization 
Parameters Value Reference 
GENERAL PROGRESSION PARAMETERS  (40, 44, 55) 
    
Progression rates (average over age)    
In-situ to Local (𝑝
0,.
 ) 0.19  
Local to Regional (𝑝
1,.
 ) 0.33  
Regional to Distant (𝑝
2,.
 ) 0.43  
Distant to Death (𝑝
3,.
 ) 0.50  
    




) 0.08  
Local (?̅?1,.) 0.14 
 




    




) 0.01  
Local (?̿?
1,.
) 0.02  
Regional (?̿?
2,.
) 0.08  
Distant (?̿?3,.) 0.27 
 
 
Note: Here ‘.’ denotes the age  
   






Table 11: Region specific input data for parameterization 
REGION-SPECIFIC DATA 
Pre-screening incidence per 1000 women per year (𝑰𝒂) (68, 69) 
Age group Peru US Colombia Uganda Philippines India Kyrgyzstan 
0-14 0.00 
0.00 
0.00 0.00 0.00 0.00 0 
15-19 0.00 0.00 0.00 0.00 0.00 0.002 
20-24 0.01 0.02 0.02 0.01 0.01 0.003 
25-29 0.05 0.09 0.04 0.07 0.05 0.04 0.049 
30-34 0.14 0.26 0.14 0.16 0.18 0.11 0.099 
35-39 0.36 0.58 0.32 0.33 0.41 0.24 0.238 
40-44 0.70 1.09 0.52 0.37 0.79 0.42 0.366 
45-49 0.91 1.72 0.83 0.85 1.14 0.60 0.493 
50-54 1.05 1.97 1.06 0.95 1.44 0.78 0.606 
55-59 1.38 2.21 1.35 0.92 1.67 0.97 0.541 
60-64 1.38 2.60 1.46 1.03 2.01 0.96 0.704 
65-69 1.52 2.84 1.31 0.91 1.84 0.95 0.66 
70-74 1.52 3.06 1.36 0.65 2.00 0.94 0.544 
75-79 1.56 3.33 1.41 0.63 2.20 0.92 0.644 
80-84 2.16 3.43 1.50 0.00 0.00 0.00 0.345 
85+ 2.14  1.28 0.00 0.00 0.00 0.247 
Distribution of stage at diagnosis in base-case (41, 68, 70-76) 
Stage Peru  US  Colombia Uganda Philippines India Kyrgyzstan 
In-Situ (𝑠
0
) 3% 4.70% 0.00% 0.00% 0.00% 0.00% 0.00% 
Local (𝑠
1
) 43% 48.30% 36.89% 19.68% 33.38% 30.74% 18.10% 
Regional (𝑠
2
) 45% 39.50% 47.09% 52.16% 53.97% 56.17% 61.90% 
Distant (𝑠
3








FORMULATION OF THE MDP MODEL 
The parameterized cancer onset and progression model was used in a Markov 
decision process model to identify an optimal screening schedule. Specifically, the problem 
was formulated as a finite-state, finite-horizon and discrete-time MDP defined by a 6-tuple 
{𝑌𝑡 , 𝐷𝑡;  𝑍, 𝑆, ℙ𝑠, 𝑅𝑠},  where 
 𝑡 = {1,2, 3… . ,100} are the decision-making stages; here, stages represent 
individual ages, i.e., 𝑡 = 𝑎, therefore, for convenience, we will use ‘age’ to refer to the 
normally used terminology of ‘stage’ in MDP models, replacing 𝑡 with 𝑎, 
 𝑌𝑎𝜖 Z is the disease state at age 𝑎, defined over the state space Z =
{[𝐻𝑎], [𝑈𝑖,𝑎], [𝐷𝑖,𝑎], 𝑀}, where [𝐻𝑎], [𝑈𝑖,𝑎], [𝐷𝑖,𝑎] are healthy, preclinical, and clinical states 
in disease stage 𝑖 ∈ {0 = 𝐶𝐼𝑆, 1 = 𝐿𝑜𝑐𝑎𝑙, 2 = 𝑅𝑒𝑔𝑖𝑜𝑛𝑎𝑙, 𝑎𝑛𝑑 3 = 𝐷𝑖𝑠𝑡𝑎𝑛𝑡} and age 𝑎, as 
in the Markov process model in the previous section, and 𝑀 denotes a mortality state, 
𝑆 is the action space which is a set of possible decision choices, and here we have 
2 possible choices, i.e., 𝑆 = {𝑆𝑐𝑟𝑒𝑒𝑛(1), 𝐷𝑜 𝑛𝑜𝑡 𝑆𝑐𝑟𝑒𝑒𝑛(0)}   
 𝐷𝑎𝜖 𝑆 is the decision taken at  age 𝑎 (choosing from set 𝑆), 
ℙ𝑠 is the transition probability matrix corresponding to action 𝑠, specifically, each 
element 𝑝(𝑖′, 𝑎, 𝑠, 𝑗) of the matrix ℙ𝑠 represents the probability of transitioning from state 




𝑅𝑠 is the immediate reward matrix corresponding to action 𝑠, specifically, each 
element 𝑟(𝑖′, 𝑎, 𝑠, 𝑗) of matrix 𝑅𝑠 represents  the immediate reward of taking action 𝑠 when 
the person is in state 𝑖′  at age 𝑎 and as a result the person transitions to state 𝑗.  
The problem is then to solve for the optimal values of 𝐷𝑎. Below is the formulation 
of the problem in the context of identifying optimal screening schedules for mammography 
considering costs of screening and monetary value per quality-adjusted life-year lived.  
The above MDP was solved using dynamic programming, which is formulated as follows. 
Let 𝑉(𝑖′, 𝑎, 𝑠) be the value of choosing action 𝑠 when the system is in state 𝑖′ at age 𝑎,  





[∑𝑝(𝑖′, 𝑎, 𝑠, 𝑗)𝑟(𝑖′, 𝑎, 𝑠, 𝑗)
𝑗∈𝑍
+∑𝑝(𝑖′, 𝑎, 𝑠, 𝑗)𝐽∗(𝑖′, 𝑎 + 1)
𝑗∈𝑍
] 




𝐽∗(𝑖′, 𝑎) =  𝑟(𝑖′, 𝑎, 𝑠∗(𝑖′, 𝑎))  + ∑𝑝(𝑖′, 𝑎, 𝑠∗(𝑖′, 𝑎), 𝑗)𝐽∗(𝑖′, 𝑎 + 1)
𝑗∈𝑍
 (6) 






𝑠∗(𝑖′, 𝑎) =  {
𝑎𝑟𝑔 𝑚𝑎𝑥𝑠∈𝑆  𝑉(𝑖
′, 𝑎, 𝑠) , 𝑖𝑓 𝑖′ = 𝑘 = {[𝐻𝑎], [𝑈𝑖,𝑎]},
𝐷𝑜 𝑛𝑜𝑡ℎ𝑖𝑛𝑔, 𝑖𝑓 𝑖′ 𝜖{[𝐷𝑖,𝑎],𝑀}
 
(7) 
Note that, with the above equations, all states in = {[𝐻𝑎], [𝑈𝑖,𝑎]}, will have the same 
optimal action because, in the absence of a diagnosis, we cannot distinguish between 
persons in preclinical cancer states [𝑈𝑖,𝑎] from healthy state [𝐻𝑎]. For persons in 
states[𝐷𝑖,𝑎] and 𝑀, i.e., for persons in clinical cancer states and deaths, respectively, the 
action is to do nothing.  
Transition `probabilities, 𝑝(𝑖′, 𝑎, 𝑠, 𝑗), are estimated using the parameterized model 
in the previous section. The specific equations are presented in Appendix A. Immediate 
rewards incorporate the costs and benefits of screening as follows. 






0, 𝑖𝑓 𝑗 𝑖𝑠 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 
𝑟𝐿𝑌 . 𝑞𝑗 + 𝑐𝑑 + 𝑐𝑖 , 𝑖𝑓𝑖
′ ∈ [𝑈𝑖,𝑎] 𝑎𝑛𝑑 𝑗 ∈ [𝐷𝑖,𝑎]
𝑟𝐿𝑌 . 𝑞𝑗 + 𝑐𝑡 , 𝑖𝑓𝑖
′ ∈ [𝐷𝑖,𝑎] 𝑎𝑛𝑑 𝑗 ∈  𝑀
𝑟𝐿𝑌 . 𝑞𝑗  𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
, and               
(8) 






0 𝑖𝑓 𝑗 𝑖𝑠 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦
𝑟𝐿𝑌 . 𝑞𝑗  +  𝑐𝑑  +   𝑐𝑖, 𝑖𝑓 𝑖
′ ∈ [𝑈𝑖,𝑎] 𝑎𝑛𝑑 𝑗 ∈ {[𝐷𝑖,𝑎]}
𝑟𝐿𝑌 . 𝑞𝑗 + 𝑐𝑡 , 𝑖𝑓𝑖
′ ∈ [𝐷𝑖,𝑎] 𝑎𝑛𝑑 𝑗 ∈  𝑀
𝑟𝐿𝑌 . 𝑞𝑗 + 𝑐𝑠 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
        
(9) 
where, 





𝑐𝑑 = − (𝑐𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑚  + 𝑐+𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠), 
𝑟𝐿𝑌 =    value-per-QALY lived,  
𝑞𝑗= QALY associated with state 𝑗, 𝑞𝑗 = {
1 𝑖𝑓 𝑗 = 𝐻𝑎
 0 𝑖𝑓 𝑗 = 𝑀
0 < 𝑞𝑗 < 1 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
,  
𝜁𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦𝑎  is the specificity of mammography at age 𝑎, 
𝑐𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑚 is the unit cost of mammography per person,  
𝑐−𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 is the cost of follow-up diagnostic tests for a false positive (per person) 
𝑐+𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 is the cost of follow-up diagnostic tests for a true positive (per person) 
𝑐𝑖 is the initial treatment cost per person, and  
𝑐𝑡 is terminal treatment cost per person, which was applied at the final year of life 
for women who die from breast cancer.  
The values of the above-mentioned parameters are noted in Table 12. 
➢ Data assumptions used for the MDP model  
Country-specific data related to the natural cancer progression, specifically the 
transition probability matrices in Tables 8 and 9, are the same data used in the two-step 
Markov process methodology and are listed in Table 10. Data related to mammography 
(film) screening are presented in Table 12. We assumed the use of film mammography in 
LMICs as the availability of digital mammography is limited in developing countries. (58) 




Further, as mammography sensitivity and specificity varied by breast density, we used 
weighted average values, weighted by the proportion of persons presenting with the 
different breast density as reported in the BCSC.  
Table 12: Parameters specific to screen-film mammography 
Parameter name Assumption (8, 64, 77, 78) 
𝜁𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦  (Specificity of film 
mammogram) for all countries (77, 78) 
Age Initial Annual Biennial Triennial 
<29 0.83000 0.83000 0.83000 0.83000 
30-34 0.85800 0.85800 0.85800 0.85800 
35-39 0.87500 0.87500 0.87500 0.87500 
40–49 0.85356 0.91812 0.90472 0.89606 
50-59 0.85576 0.91974 0.90498 0.90013 
60-69 0.86576 0.92974 0.91459 0.91013 
70-79 0.88384 0.93602 0.92127 0.91974 
 
𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦  (Sensitivity of film 
mammogram) for all countries (77, 78) 
 
Age Initial Annual Biennial Triennial 
<29 0.66700 0.66700 0.66700 0.66700 
30-34 0.81500 0.81500 0.81500 0.81500 
35-39 0.76100 0.76100 0.76100 0.76100 
40–49 0.87158 0.75644 0.8173 0.83026 
50-59 0.88126 0.77184 0.82155 0.83783 
60-69 0.90754 0.80298 0.85269 0.86897 
70-79 0.92611 0.84373 0.88126 0.8964 
 
𝜁𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦  (Specificity of film 




 45-49 0.904 
 50-54 0.916 
 55-59 0.922 
 60-64 0.925 
 65-69 0.93 
 70-74 0.937 
 75-89 0.942 
 
𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦  (Sensitivity of film 
mammogram) for US validation and 




 45-49 0.701 
 50-54 0.744 
 55-59 0.744 
 60-64 0.744 




 70-74 0.798 
 75-89 0.807 
 
𝜁𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦  (Specificity of film 
mammogram) for all country 1995 era 




 45-49 0.823 
 50-54 0.816 
 55-59 0.84 
 60-64 0.856 
 65-69 0.86 
 70-74 0.869 
 75-89 0.88 
 
𝑐𝑠𝑐𝑟𝑒𝑒𝑛 (Screening cost) for all 
countries except US (67) 
2.45 USD 
𝑐𝑠𝑐𝑟𝑒𝑒𝑛 (Screening cost) for US (77) 81.35 USD 
𝑐𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 (Cost of follow-up tests if 
diagnosed) for all countries except US 
(67) 
True positive, $ False 
positive, $ 
551.36 72.18 
𝑐𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 (Cost of follow-up tests if 
diagnosed) for US  (79) 
Age group True positive, $ False positive, $ 
40–49 2187.89 229.1612 
50–64 2053.74 271.6121 
65–74 2065.13 272.353 
≥75 1741.3 280.5171 
 
𝑐𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡  (Cost of treatment by stage 
at diagnosis) for US  (79) 
Stage Initial, $ Terminal, $ 
In situ 13055 35335 
localized 13055 35335 
Regional 24682 41825 
Distant 38119 58665 
 
𝑐𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡  (Cost of treatment by stage 
at diagnosis) for all countries except 
US (67) for initial cost; proportion of 
terminal to initial cost for US used in 
calculation of terminal cost for all other 
countries 
Stage Initial, $  Terminal, $ 
In situ 218.01 590 
localized 218.01 590 
Regional 464.58 787 
Distant 684.84 1053 
 
𝑞𝑗= quality-adjusted life-years 
associated with state 𝑗  
𝑞 = [1 ,1, 1, 1 ,1, 0.992, 0.992, 0.971, 0.46, 0] corresponding 
to stage [𝐻𝑎 ,𝑈𝑖𝑛−𝑠𝑖𝑡𝑢 ,𝑈𝑙𝑜𝑐𝑎𝑙 , 𝑈𝑟𝑒𝑔𝑖𝑜𝑛𝑎𝑙 , 𝑈𝑑𝑖𝑠𝑡𝑎𝑛𝑡 , 𝐷𝑖𝑛−𝑠𝑖𝑡𝑢 , 








➢ Results for Base case and Uncertainty analysis on CIS pathways 
Table 13 : Uncertainty analysis on CIS pathways- Comparing screening age intervals 
















































1 51-51 52-52 60-60 53-53 47-47 55-55 54-54 60-60 56-56 52-52
2 50-56 50-55 54-62 52-60 44-48 51-57 51-56 55-63 54-60 50-54
3 46-57 50-57 51-63 52-62 44-51 51-60 50-58 52-64 52-62 44-55
4 45-60 50-60 52-65 50-63 44-52 47-61 50-60 52-65 51-63 45-56
5 44-61 46-61 51-66 50-64 43-53 46-62 45-61 50-66 50-64 45-57
6 44-62 46-62 51-70 50-66 42-54 43-62 45-61 50-67 51-66 45-57
7 41-62 46-63 51-71 47-66 42-55 44-63 44-62 50-70 50-66 42-58
8 40-63 45-63 47-71 46-67 41-56 43-64 45-63 48-70 47-67 42-58
9 42-64 45-64 46-71 46-70 40-56 41-64 43-63 47-71 46-67 43-59















































1 54-54 51-51 60-60 53-53 46-46 52-52 52-52 55-55 54-54 45-45
2 50-56 51-56 53-61 53-60 44-50 48-55 50-55 54-60 51-56 43-48
3 47-58 52-60 50-62 51-62 42-52 45-56 47-57 50-60 51-60 41-50
4 46-60 50-60 51-64 50-63 43-54 43-58 45-57 51-62 47-61 41-52
5 46-61 46-61 51-65 50-64 43-55 42-58 44-59 48-63 47-62 41-54
6 45-62 45-61 50-66 48-65 42-56 42-60 43-60 46-64 45-62 41-54
7 44-62 45-62 47-67 48-66 42-55 40-60 42-60 45-64 44-63 41-55
8 40-62 45-63 48-67 45-66 40-57 40-61 40-61 44-65 43-63 39-56
9 41-63 44-63 44-68 47-67 41-58 41-61 42-61 44-66 44-64 38-57















































1 54-54 52-52 53-53 54-54 50-50 54-54 54-54 53-53 54-54 51-51
2 50-56 51-56 52-57 51-56 45-53 51-57 51-56 53-60 54-60 45-52
3 48-58 51-58 51-60 51-60 45-55 47-58 50-58 52-62 51-61 45-54
4 45-59 45-58 50-62 46-60 44-56 46-60 50-60 51-63 51-62 43-55
5 44-60 45-60 46-63 47-61 42-57 46-61 45-61 50-64 50-63 44-56
6 44-61 43-60 46-64 46-62 41-57 43-62 45-61 48-66 50-64 42-57
7 42-61 44-61 44-64 44-63 40-58 42-62 44-62 47-66 45-64 42-57
8 41-61 42-61 43-65 44-63 41-58 41-63 45-63 48-67 46-65 41-57
9 40-62 42-62 44-66 41-64 41-58 40-63 43-63 47-68 45-66 40-58







Table 14: Uncertainty analysis on CIS pathways- Comparing LY saved per 1000 women 
and cost per 1000 women between base case and CIS uncertainty cases 1 to 5 for Peru 
 
Table 15 : Uncertainty analysis on CIS pathways- Comparing LY saved per 1000 women 































































1 19 12 5 8 12 145,555    135,830    128,879    138,641  131,019   
2 31 20 11 14 22 234,087    193,458    186,664    188,370  193,832   
3 44 28 15 20 30 335,719    250,243    244,600    244,033  252,667   
4 54 33 20 25 36 417,771    299,973    292,004    301,988  314,130   
5 62 38 23 30 42 507,797    360,229    348,638    351,312  373,950   
6 70 44 26 34 47 611,731    416,699    388,921    405,595  415,552   
7 78 49 29 38 52 703,042    473,416    435,310    466,612  471,040   
8 84 53 32 42 56 804,138    528,402    481,700    516,815  527,786   
9 88 57 36 45 60 883,702    561,846    556,630    563,390  586,271   




























































1 22 16 8 12 14 143,592      134,395  130,418   137,677  127,746      
2 39 27 16 21 24 233,173      191,009  187,496   188,437  186,679      
3 50 38 23 30 33 313,073      249,181  245,477   245,625  248,712      
4 63 46 29 37 41 402,624      300,163  294,926   302,712  306,822      
5 73 52 35 44 48 504,903      355,826  352,050   353,801  367,555      
6 82 59 40 49 53 598,244      400,630  402,268   407,939  410,372      
7 89 64 44 55 60 676,824      467,218  449,183   466,074  489,752      
8 82 71 48 60 64 782,642      530,500  502,338   519,285  524,707      
9 103 76 53 65 68 873,009      587,582  559,573   576,570  579,822      





Table 16: Uncertainty analysis on CIS pathways- Comparing LY saved per 1000 women 




Table 17: Uncertainty analysis on CIS pathways- Comparing LY saved per 1000 women 































































1 19 14 8 10 14 150,101    141,099 133,963 145,308 130,190 
2 36 25 15 17 24 234,276    193,462 189,975 190,152 191,434 
3 48 32 22 24 33 330,601    238,539 245,286 243,093 251,214 
4 59 41 27 31 41 405,391    293,906 288,582 295,912 306,530 
5 68 48 33 36 47 493,806    351,476 340,344 342,362 364,106 
6 76 55 38 42 53 591,798    407,769 391,987 396,270 421,108 
7 84 61 42 46 59 673,330    464,355 442,614 447,780 478,109 
8 93 65 47 52 63 777,407    509,811 494,524 505,944 513,735 
9 98 70 51 55 67 848,866    545,765 555,445 547,978 564,721 






























































1 8 5 4 5 6 91,345    85,011   86,350    86,459    88,105   
2 14 10 7 9 11 154,919  127,003 120,295 128,808 136,497 
3 20 13 11 12 15 233,253  170,886 164,531 162,407 183,138 
4 25 17 13 16 18 300,128  216,249 201,747 207,880 229,325 
5 29 20 17 18 20 381,712  259,695 245,712 248,120 273,105 
6 32 23 19 22 23 439,545  299,160 283,915 293,876 319,978 
7 36 26 22 24 25 518,308  347,394 328,311 335,559 347,367 
8 39 28 24 27 27 587,118  391,184 369,304 374,402 381,908 
9 40 30 26 28 29 664,715  412,565 409,362 411,051 424,742 






Table 18: Uncertainty analysis on CIS pathways- Comparing LY saved per 1000 women 
and cost per 1000 women between base case and CIS uncertainty cases 1 to 5 for 
Kyrgyzstan 
 
Table 19: Uncertainty analysis on CIS pathways- Comparing LY saved per 1000 women 
































































1 13 10 7 8 9 116,721 108,086 110,971 109,305 105,793 
2 24 18 12 15 16 206,426 164,510 167,358 167,012 166,500 
3 32 23 17 20 22 308,108 220,560 217,740 216,303 224,016 
4 41 30 21 25 28 400,008 282,372 273,749 277,542 285,087 
5 47 34 25 30 33 479,079 332,908 333,379 333,252 344,066 
6 52 39 28 34 37 583,134 395,037 383,413 390,406 405,456 
7 58 43 32 38 40 673,856 451,566 444,593 450,309 463,716 
8 62 47 35 41 43 775,180 512,664 502,249 508,647 498,950 
9 66 50 38 44 46 865,656 569,836 556,003 563,480 553,830 






























































1 10 7 4 5 6 113,399 104,230  106,409 105,523 102,594 
2 17 12 8 9 11 194,266 156,378  149,814 148,734 159,199 
3 23 17 11 14 16 273,828 207,211  199,690 201,016 211,728 
4 29 20 14 17 20 358,119 252,122  250,064 250,794 268,270 
5 33 24 17 20 23 440,244 306,916  294,906 294,994 319,945 
6 38 27 19 23 26 532,206 359,809  344,259 345,711 376,286 
7 42 30 22 26 28 612,906 413,779  396,251 401,992 429,599 
8 45 32 24 28 31 679,610 456,563  439,268 449,277 482,913 
9 48 35 26 31 33 777,183 513,974  488,576 497,739 514,292 
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